预约演示
更新于：2026-03-20
Rilpivirine Hydrochloride
盐酸利匹韦林
更新于：2026-03-20
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-05-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C22H19ClN6 |
InChIKeyKZVVGZKAVZUACK-BJILWQEISA-N |
CAS号700361-47-3 |
关联
114
项与 盐酸利匹韦林 相关的临床试验NCT06336434
Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults With HIV-1
This is a Phase I/II, multicenter, open-label, non-randomized study with four groups to characterize the pharmacokinetics and safety of Cabotegravir (CAB) and Rilpivirine (RPV) long-acting injectable (LA) during pregnancy and postpartum among people with HIV-1 viral suppression and their infants.
开始日期2025-05-01 |
NCT06646562
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.
People Living with HIV-1 (PLHIV) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretroviral treatment (ART), allowing them to stabilize the HIV-infection and to live a normal life despite the infection. The present study is encouraged to demonstrate that efficacy and security of CAB LA + RPV LA treatment's on this population remains the same compared to younger population of patients. This study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters, as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them. Psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffering certain psychological disorders.
开始日期2025-03-03 |
申办/合作机构 |
TCTR20250218001
Changes in sleep quality following a switch of antiretroviral regimen from three to two drugs: A comparative study between dolutegravir and lamivudine (DTG + 3TC) and dolutegravir and rilpivirine (DTG + RPV)
开始日期2025-02-04 |
申办/合作机构- |
100 项与 盐酸利匹韦林 相关的临床结果
登录后查看更多信息
100 项与 盐酸利匹韦林 相关的转化医学
登录后查看更多信息
100 项与 盐酸利匹韦林 相关的专利（医药）
登录后查看更多信息
1,694
项与 盐酸利匹韦林 相关的文献（医药）2026-04-09·Sexual Health
Implementation of a Hospital in the Home model for delivery of long-acting injectable antiretroviral therapy to people living with HIV: development, integration and early experience
Article
作者: Trevillyan, Janine ; Dowling, Ray ; Rose, Morgan ; Lam, Connie ; Bangham, Madeleine ; Narayanasamy, Shanti ; Sullivan, Angela
Background:
Long-acting injectable cabotegravir/rilpivirine provides an alternative to daily oral antiretroviral therapy for people living with HIV, but is limited by its clinic-based delivery model. The aim of this study was to describe the implementation and early outcomes of a Hospital in the Home (HITH) program delivering long-acting injectable antiretroviral therapy within an Australian tertiary health service.
Methods:
A structured protocol for HITH-based delivery of cabotegravir/rilpivirine was developed at a single tertiary centre in Melbourne, Australia. The program was established through collaboration between infectious diseases clinicians, HITH physicians, nursing leadership and pharmacy. Processes were designed for patient selection, induction dosing, medication storage, cold-chain transport, clinical documentation and escalation of care. HITH staff received targeted training in HIV care, injection technique and stigma-sensitive communication. Following the first dose in clinic, subsequent injections were administered at home every 8 weeks, with pre-visit telephone assessments, post-dose telehealth reviews and routine pathology monitoring.
Results:
The program was integrated into existing HITH infrastructure without additional resources. One patient has completed five treatment doses, all delivered safely within dosing timeframes. Laboratory monitoring confirmed continued viral suppression. Nursing staff reported high satisfaction, describing the model as patient-centred and professionally rewarding. Operationally, coordination between HITH pharmacy, nursing and infectious diseases teams was efficient and sustainable.
Conclusion:
HITH delivery of cabotegravir/rilpivirine is feasible, safe and well accepted, providing a scalable, decentralised model for HIV treatment in Australia.
2026-04-01·AIDS
Is baseline genotyping still necessary before initiating long-acting cabotegravir and rilpivirine?
Article
作者: Martinez, Esteban
2026-04-01·AIDS
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort
Article
作者: Gimeno García, Alejandra ; Pedrero-Tomé, Roberto ; Cabello Úbeda, Alfonso ; Bernardino, José I. ; Buzón-Martín, Luis ; Alemán Valls, María Remedios ; Torralba González de Suso, Miguel ; Bernal Morell, Enrique ; Calzado Isbert, Sonia ; Morano, Luis ; Crusells Canales, María José ; Martínez Álvarez, Rosa María ; Rodríguez, Adrián ; de Andrés David, Carlos ; Vivancos, María Jesús ; Fanjul, Francisco ; Martín-Torres, Juan ; Aguilera García, María ; Díaz de Santiago, Alberto ; Hidalgo Tenorio, Carmen ; Cabello Clotet, Noemí ; Troya, Jesús ; Vinuesa García, David ; Tiraboschi, Juan ; Galindo Puerto, María José
Objectives::
Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching to LAI CAB+RPV with or without available genotypes in the Spanish RELATIVITY cohort.
Design::
RELATIVITY is a multicenter, ambispective cohort study assessing the effectiveness and safety of LAI CAB+RPV in adults with HIV across 58 centers in Spain.
Methods::
Posthoc analysis of 3146 participants, focusing on the availability of genotypic resistance data before switching.
Results::
Of the 3146 participants, 53.5% (
n
= 1682) did not have genotypes available. The median follow-up was 13.3 months [interquartile range (IQR) 8.6, 18.9] in the no-genotype group and 14.9 months (IQR 9.0, 19.2) in the genotype group (
P
= 0.003). Both groups maintained high virological suppression rates (>93%) up to the 23rd month of follow-up, with no significant differences observed in virological or immunological outcomes. Virologic failure rates (0.5% vs. 1.0%;
P
= 0.476) and permanent discontinuation rates (6.1% vs. 6.6%;
P
= 0.804) were similar. Of the 20 participants with virologic failure, 12 had genotype data. After resuming oral antiretroviral therapy, 8 of those with and 4 of those without the genotype achieved undetectable viral loads. Adherence to injection schedules and changes in body mass index were comparable.
Conclusions::
In this large real-world cohort, the absence of genotypic data did not affect LAI CAB+RPV effectiveness in virologically suppressed PWH. Limitations, including ambispective design, short follow-up, and low non-B subtype prevalence, may limit generalizability.
336
项与 盐酸利匹韦林 相关的新闻（医药）2026-03-19
免费医学论文下载-乳腺细胞中GRHL2的机制性解离及PR转录共调控
玛琳·T·阿茨，安娜·诺丁，克劳迪奥·坎图，安东尼乌斯·L·范·博克斯特尔，蕾妮·范·阿梅隆根
发布日期：2026年3月17日
摘要
基因表达由复杂的转录网络控制，其中转录因子及其对应的增强子整合发育和环境信号。孕酮受体（PR）是一种激素激活的转录因子，对乳房发育和生理至关重要，但它如何与染色质及谱系特异性辅因子相互作用尚不清楚。通过无偏的方法，我们鉴定了上皮转录因子颗粒头样2（GRHL2）是激素响应性乳腺癌细胞PR活性的关键共调控因子。我们表明GRHL2与PR的相互作用与孕激素无关。在孕激素刺激下，GRHL2和PR都会被招募到目标基因的远端增强子元件。此外，结合GRHL2和PR的元件通过染色质环路进行空间连接，调控共享靶点。这些发现揭示了一种此前未被发现的机制，即GRHL2和PR通过染色质结合和三维基因组结构修饰协调基因调控，使GRHL2成为类固醇激素受体功能的关键调节因子。
作者简介
基因表达受到调控网络的严格控制，其中转录因子整合了发育和环境信号。激素是这类信号中的重要类别。在乳腺组织中，孕酮激素对正常发育和功能至关重要。孕酮结合其受体——孕酮受体，这是一种调节孕酮响应基因活性的DNA结合蛋白。然而，孕酮受体是否以及如何与谱系特异性辅因子协同调控基因表达，至今仍未完全明了。本研究中，我们确认GRHL2是激素响应型乳腺癌细胞孕酮受体的关键共调控因子。我们发现，这两种蛋白即使在没有激素刺激的情况下也会相互作用。在孕酮暴露时，这两种蛋白都会被招募到调控共享目标基因的调控区。重要的是，我们证明这些调控区域通过长距离DNA环路物理连接，实现基因表达协调。我们的发现共同为激素驱动的基因调控提供了新的见解，并强调GRHL2是乳腺细胞中孕酮受体功能的重要贡献者。
数据
Table 1Fig 1Fig 2Fig 3Fig 4Fig 5Fig 6Table 1Fig 1Fig 2Fig 3
引用： Aarts MT， Nordin A， Cantù C， van Boxtel AL， van Amerongen R （2026） 乳腺细胞中GRHL2的机理性解离及PR转录共调控。PLoS Genet 22（3）： e1012088。 https://doi.org/10.1371/journal.pgen.1012088
编辑： 莫妮卡·P·科莱亚科沃，美国哈佛医学院
收到： 2025年12月10日;接受： 2026年3月9日;发布日期： 2026年3月17日
版权所有： © 2026 Aarts 等。这是一篇开放获取文章，根据知识共享署名许可协议（Creative CC Attribution License）发布，允许在任何媒介中不受限制地使用、分发和复制，前提是必须注明原作者和来源。
数据可用性： 所有相关数据均包含在手稿及其支持信息文件中。原始数据可通过开放科学框架获取，时间为 https://osf.io/9uqsw。
资金来源： RvA感谢荷兰科学研究组织（OCENW）的资助。KLEIN.169 + NWO ALW VIDI 864.13.002。CC感谢Cancerfonden（21 1572 Pj和24 3487 Pj 01 H）、瑞典研究理事会、Vetenskapsrådet（2021–03075和2023-01898）、Additional Ventures（SVRF2021-1048003）、林雪平大学、Joanna Cocozzas基金会的支持。CC是Wallenberg分子医学（WCMM）和SciLifeLab的会士，并获得Knut和Alice Wallenberg基金会的慷慨资助。MTA感谢对Claudio Cantù实验室进行CUT&RUN实验的研究访问的资金支持，资金来自Landelijk Netwerk voor Vrouwelijke Hoogleraren（LNVH，2024/2025年女性生物学进步基金）和Genootschap ter bevordering van Natuur-， Genees- en Heelkunde。资助方在研究设计、数据收集与分析、发表决策或手稿准备中没有参与。
利益冲突： 作者们宣称不存在竞争利益。
简介
基因表达受到复杂的转录网络严格调控，其中DNA结合转录因子（TFs）起着核心作用。这些网络通过整合细胞内在的发育线索和外在环境信号，决定基因何时何地表达[1]。TFs结合调控DNA元件中不同的基序，调节转录输出[2–4]。TFs不单独作用，而是以组合组装形式工作，并加入额外的转录因子、辅因子和染色质重塑因子。这种分层调控结构确保不同基因表达项目以细胞类型和情境特异性方式执行，使得专门化的细胞身份在整个发育过程中出现，并在成年组织中得到忠实维护[5,6]。
类固醇激素受体是一类独特的转录因子，其特点是作为配体激活受体和基因表达的直接调节者。与许多具有固定性DNA结合活性的转录因子不同，类固醇受体功能由特定激素的存在外在调控。配体结合后，这些受体在细胞核中积累，并动态地与染色质上的激素反应元件结合，调控转录程序[7]。
这一类受体包括雌激素受体（ER），它具有独特的DNA结合基序，以及3-酮类固醇受体，它们共享共识序列：孕酮受体（PR）、矿物皮质激素受体（MR）、糖皮质激素受体（GR）和雄激素受体（AR）。ER和PR由卵巢激素激活，是产后乳腺组织发育的关键调控因子[8–10]。在该组织中，它们几乎完全在一类腔内细胞中表达，称为成熟腔内细胞或激素感知细胞。鉴于ER在激素依赖性乳腺癌中的作用（及其靶向性），大多数注意力都集中在解决ER的信号机制上。PR信号的分子机制尚不完全明了，但它调控了多条细胞内在和副分泌信号通路。这些通路促进局部增殖和基底膜重构[11]，进而支持妊娠期间导管的生长、侧支和肺泡生成[10]。因此，PR对乳腺发育和生理至关重要，抗孕激素也被积极从乳腺癌预防和治疗的角度探讨[12]。
类固醇受体如ER和PR并非孤立作用，而是在涉及额外相关蛋白的复杂调控网络中发挥作用。其中，先锋因子（一类能够调节染色质可及性）的转录因子[13]，越来越被认可为类固醇受体活性的关键协调控因子，尤其是在激素依赖性癌症中[14]。例如，ER与FOXA1和GATA3等先驱因子合作，促进其目标基因的转录激活[15–20]。相比之下，公关在类似互动中的程度仍不十分理解。Grainyhead-like 2（GRHL2）最近被认为是激素受体阳性癌症（包括乳腺癌）中的潜在先驱因子[21]。然而，迄今为止几乎所有研究都聚焦于GRHL2在内质网和雌激素信号传导中的作用，其在PR和孕激素介导调控中的作用尚未深入探讨[22–26]。
本研究中，我们鉴定并剖析PR与GRHL2（GRHL蛋白家族成员）之间的功能转录相互作用。该家族包括三种进化保守的先驱转录因子（GRHL1、GRHL2和GRHL3），在上皮细胞中发挥重要作用[27,28]。它们共享高度保守的DNA结合结构域，并表现出显著的结构同源性[29,30]。尽管有这些相似之处，GRHL家族成员展现出独特的时空表达模式，并执行独特的上皮转录程序，支撑其特定的生物功能。
本文结合基因组学、转录组学和蛋白质组学方法，首次对人类乳腺癌细胞中PR和GRHL2的协调转录活性进行了机理性剖析。我们表明PR和GRHL2可以独立于孕酮相互作用，并且在孕酮刺激下常常共占增强子元素。此外，GRHL2 是调控一组 PR 靶基因所必需的。染色质环路分析进一步揭示了共享（即同一DNA元素）和不同（即线性分离的DNA元素）PR和GRHL2结合事件如何在三维染色质空间中长距离收敛，调控共同靶点。我们的发现共同揭示了由GRHL2和三维基因组结构塑造的新PR基因调控层。
选举结果
GRHL2与PR以孕酮无关的方式物理相互作用
为了在无偏载人机中鉴定GRHL2的核相互作用体，我们在T47DS细胞中进行了内源蛋白（RIME）快速免疫沉淀质谱（RIME）[31]（图1A）。在剥离血清、非激素刺激条件下，我们鉴定出2352个GRHL2相关蛋白，包括若干此前报道的核相互作用物，如FOXA1 [18]、KMT2C/D （MLL3/4） [32]、GRHL1 [27,33]（图1B）。在这2352个相互作用体中，共有103个被标记为转录因子或染色质关联/修饰蛋白，基于Panther分类系统[34]。我们通过MaxQuant蛋白识别分数对这些蛋白质进行了排名，以识别并突出高置信度候选者（图1C）。有趣的是，得分最高的几个相互作用体，如CTBP1、MTA2、SMARCC2、SMARCD2、CHD3和PHF6，都参与染色质可及性和重塑，这符合GRHL2作为染色质可及性先驱因子和调节因子的既定功能[28]（见图1C）。
缩略图 下载：
PPT幻灯片
巴布亚新几内亚大图
多伦多国际电影节原始图片
图1。 对GRHL2相关蛋白的RIME分析显示，GRHL2-PR的相互作用与孕酮无关。
A）内源性蛋白快速免疫沉淀质谱（RIME）[31]方案的示意概述，该方案用于识别激素耗竭和孕激素处理条件下的GRHL2相互作用体。B）火山图，展示激素耗竭条件下GRHL2 RIME与IgG对照组的结果。每个灰色点代表质谱中识别的单一蛋白质。灰色虚线表示Log2FC（-3,3）和-Log10（p值）截止值（0.05）。共有2352种蛋白质符合这些标准，因此被鉴定为GRHL2相互作用物。红色高亮点为一些此前报道的GRHL2互助体示例[18,27,32,33,35]。C）根据Panther分类系统，呈现103个GRHL2相互作用体，作为转录因子或染色质关联/修饰蛋白过滤的词云[34]。蛋白质名称的大小和颜色代表基于MaxQuant蛋白识别得分（Andromeda分数和）对已识别相互作用的置信度，反映了蛋白质检测的相对置信度。D）在激素耗竭及PR激动剂R5020刺激条件下4小时1 nM相互作用的共免疫沉淀法西墨迹验证。西部印迹显示GRHL2和PR，A和B异构体，输入蛋白和免疫沉淀样本。E）火山图，展示GRHL2 RIME在激素耗竭与4小时1 nM R5020治疗条件下的结果。每个灰色点代表质谱中识别的单一蛋白质。灰色虚线表示Log2FC（-3,3）和-Log10（p值）截断值（0.01）。只有2个蛋白（1个缺失，1个增加）符合这些标准，并被鉴定为高置信度的孕酮依赖性GRHL2相互作用物。蓝色高亮点表示失去GRHL2的蛋白质，红色高亮点表示获得GRHL2结合的蛋白质。
https://doi.org/10.1371/journal.pgen.1012088.g001
出乎意料的是，PR成为这些剥离血清条件下最强健的GRHL2相互作用体之一，表明两者之间存在激素独立关联（见图1B-C）。我们通过在激素剥离载体处理和激素剥离的R5020（PR激动剂）处理的T47DS细胞中共同免疫沉淀验证了该相互作用，确认GRHL2–PR相互作用未受孕激素刺激影响（见图1D）。有趣的是，我们发现GRHL2主要结合PR的全长且转录活性的同工型PR-B，但不结合PR-A（见图1D）。
由于GRHL2-PR相互作用不依赖于孕酮的存在，我们想知道孕酮是否以及如何改变GRHL2的相互作用组。因此，我们在合成孕激素R5020处理4小时后，也在T47DS细胞中进行了GRHL2 RIME检测（见图1E）。与未治疗状态的比较显示，仅有少量相互作用受影响。仅有一种蛋白TAB2在孕激素刺激下与GRHL2的相互作用丧失。相反，同样只有一种蛋白CCNB1仅在激素存在时被招募（见图1E）。这些差异性相互作用蛋白未被归类为转录因子或染色质调控因子，迄今文献中尚无与孕酮或PR直接相关性的报道，尽管两者都被认为与乳腺癌有关[36,37]。由于GRHL2-PR相互作用本身尚未被功能性表征，我们后续分析将重点放在这一潜在的转录伙伴关系上。
GRHL2和PR DNA结合的全局定位揭示了增强子位点的共占性
为确定GRHL2与PR的相互作用是否发生在共享基因组位点，我们重新分析了T47D细胞中两份此前已发布的CHIP-seq数据集，分别针对GRHL2[23]和PR[38]。值得注意的是，GRHL2数据集是在剥离血清条件下生成的，因此代表了雌激素和孕激素耗尽条件下GRHL2的结合。PR数据集同样在剥离血清条件下生成，但这里细胞同时被1 nM R5020刺激。在本次分析中，我们识别出46,746个PR峰和28,925个GRHL2峰。其中6,335个位点重叠，占PR的13.5%，GRHL2结合事件总数的21.9%（见图2A）。图2B展示了这样一个GRHL2-PR共享区域的例子。通过热图可视化PR和GRHL2结合在仅PR、仅GRHL2和GRHL2-PR重叠位点的结合，显示最强的PR和GRHL2信号集中在重叠区域，尽管部分GRHL2信号也在最强PR峰被检测到，反之亦然（见图2C-D）。GRHL2和PR信号在定义的重叠峰之外共存的观察表明，它们的功能协作很可能超出了我们分析中严格阈值化的位点（图2C-D）。对PR和GRHL2 ChIP-seq峰的基因组注释显示，PR（~66%）和GRHL2（~57%）位点，包括重叠的PR-GRHL2（~61%）位点，都位于远端基因间或内含子区域的增强子处（见图2E）。值得注意的是，GRHL2-PR重叠区域对应于R5020刺激条件下由H3K27ac标记的活性增强子（见图2F）。GRHL2峰比含PR峰更频繁地位于转录起始位点（TSS）以内（约占所有GRHL2峰的25%，GRHL2-PR共享位点的~17%）<（见图2E）。此外，根据ATAC-seq（图2G）确定，GRHL2–PR重叠区域比仅PR或仅GRHL2的染色质更常与可及染色质相关（图2G）。一致地，siRNA介导的GRHL2敲低改变了GRHL2–PR共享位点的染色质可及性，表明GRHL2有助于维持这些区域的可及性（见图2G）。基序分析确认PR和GRHL2基序在单独峰和重叠峰中均有强烈富集（S1A图）。此外，PR或GRHL2结合区以及GRHL2-PR重叠区被富集为FOXA1基序。此外，TEAD基序在GRHL2结合区（包括GRHL2-PR重叠位点）中特异性富集。这表明FOXA1和TEAD在乳腺组织中作用于与GRHL2和PR相似的调控区域（S1A见图）。
缩略图 下载：
PPT幻灯片
巴布亚新几内亚大图
多伦多国际电影节原始图片
图2。 GRHL2和PR在基因组中共同结合调控区域。
A）维恩图，显示未处理的GRHL2[23]芯片序列与1 nM R5020刺激PR[38]ChIP-seq峰的重叠。如果峰重叠至少1个碱基对，则视为重叠。B）两个PR峰和GRHL2峰重叠的代表性例子。数据在IGV浏览器中进行可视化[39]。NT = 未治疗。C）热图显示未处理的GRHL2结合ChIP-seq信号[23]和1 nM R5020在仅PR、仅GRHL2和GRHL2-PR共占的基因组区域刺激PR[38]。D）信号强度图，显示GRHL2[23]和1 nM R5020在仅PR、仅GRHL2和GRHL2-PR共占基因组位点的累计ChIP-seq信号[38]。E）所有PR、所有GRHL2或GRHL2-PR共享峰的基因组注释，均由ChIPseeker进行[40,41]。位点被注释为5'UTR、先驱子、第一外显子、其他外显子、第一内含子、其他内含子、3'UTR内含子、远端基因间区及下游。推动器区域分为三个子类别，定义为：< TSS的1 kb、1-2 kb的TSS或2-3 kb。F）信号强度图，显示H3K27ac在仅PR、仅GRHL2和GRHL2-PR共占基因组位点30分钟内，R5020刺激T47D细胞的累计ChIP-seq信号[42]。G）信号强度图，显示siControl和siGRHL2 T47D细胞在仅PR、仅GRHL2和GRHL2-PR共占基因组位点的累计未处理ATAC信号[43]。
https://doi.org/10.1371/journal.pgen.1012088.g002
接着我们询问孕酮是否以及如何调节GRHL2染色质结合。为深入了解此类结合动态，我们在激素缺乏T47DS细胞中，在未刺激和孕激素刺激条件下对GRHL2和PR进行了CUT&RUN分析。在无激素刺激且血清剥离条件下，我们鉴定出7,039个GRHL2峰，而在4小时R5020处理后识别出5,520个GRHL2峰（见图3A）。其中只有713个地点重叠。此外，R5020刺激下GRHL2信号显著增强，表明GRHL2染色质结合在R5020刺激下既重新分布又增强（见图3A）。这种效应不太可能仅仅通过GRHL2蛋白水平的增加来完全解释，因为4小时的R5020处理仅略微提升了GRHL2蛋白水平，最多增加了20%（且统计学上无显著意义）（S2A-B图）。对于PR，我们在R5020刺激4小时后识别出3033个峰值。重叠GRHL2和PR峰显示，GRHL2和PR结合位点仅在R5020处理条件下重叠（158位点，图3B，S1B-S1C）。 对这些位点的基序分析确认了PR和GRHL2基序的富集，如预期（图3C）。鉴于PR和GRHL2在孕酮存在和缺失时均生化相互作用（图1），这表明PR的活化促进GRHL2对孕酮反应性染色质元件的招募。
缩略图 下载：
PPT幻灯片
巴布亚新几内亚大图
多伦多国际电影节原始图片
图3。 CUT&RUN揭示黄体酮刺激后的GRHL2重分布。
A）显示CUT&RUN GRHL2信号在未处理且4小时1 nM R5020刺激条件下的状态，分布于激素耗竭状态（GRHL2缺失）、激素枯竭和R5020刺激条件下结合GRHL2（GRHL2保守）或GRHL2结合于R5020刺激条件下（GRHL2增益）的站点。B）热图显示GRHL2在未处理且4小时1 nM刺激条件下的CUT&RUN信号，以及仅PR时GRHL2和4小时1 nM R5020刺激条件下的PR信号，GRHL2在R5020刺激条件下结合，GRHL2在R5020刺激与PR共占CUT&RUN峰值时表现。C）通过HOMER基序分析确定，所有未处理的GRHL2峰、所有R5020处理的GRHL2峰、所有R5020处理的PR CUT&RUN峰，以及所有GRHL2处理后的R5020和PR共占CUT&RUN峰中富集的前5个转录因子基序[44]。
https://doi.org/10.1371/journal.pgen.1012088.g003
将我们的CUT&RUN信号绘制在图2中识别的GRHL2结合峰和GRHL2-PR共享ChIP-seq峰上，也证实了这些位置GRHL2结合依赖性的增加（S1D图）。在未处理条件下观测到的CUT&RUN GRHL2信号虽然强度有所降低，但也与GRHL2结合和GRHL2–PR共享的ChIP-seq峰有大量重叠。值得注意的是，我们在R5020刺激条件下的PR切断和运行信号不仅在PR束缚和GRHL2-PR共享ChIP-seq峰处富集，也在仅GRHL2的ChIP-seq峰处得到浓缩。这些综合观察表明，出于某种原因，T47DS中R5020刺激的GRHL2切断与运行状态与此前报告的T47D未刺激GRHL2 ChIP-seq数据相呼应。
综合来看，PR和GRHL2可以独立结合DNA，但也可能在增强子区域重叠。此外，在孕激素刺激下，GRHL2染色质结合会被强化和重新分布。这支持了PR和GRHL2协同协同进行激素依赖转录调控的模型。
GRHL2和PR共同调控参与乳腺发育的部分基因
接下来，我们试图识别由GRHL2和PR调控的转录程序。为此，我们通过稳定的shRNA介导敲低GRHL2（S2A-B图）生成了T47DS细胞，并对野生型和GRHL2敲低T47DS细胞进行了RNA测序，分别用R5020进行4小时或R502024小时处理。主成分分析（PCA）显示，97%的基因表达变异由R5020刺激（PC1）或GRHL2敲低（PC2）解释，证实了对实验条件的强健转录反应（S2C见图）。为识别直接且持续的GRHL2与PR共调基因，我们基于三项标准进行了严格筛选：1）R5020处理4小时后基因表达差异，2）R5020处理24小时后基因表达差异显著，3）GRHL2耗竭后R5020转录反应显著改变（见图4A）).应用这些标准，我们识别出298个同时受PR和GRHL2调控的基因（见图4B）。基因本体富集分析识别出参与信号转导和细胞过程的基因，以及包括腺体发育在内的若干发育过程（见图4C）。我们验证了qRT-PCR对选定目标基因（包括GRHL2本身、IGFBP5和TGFB2）的表达变化（见图4D）。这些结果共同揭示了大量基因由GRHL2和PR共同调控，证实了它们在激素响应型乳腺癌细胞中的共调作用。
缩略图 下载：
PPT幻灯片
巴布亚新几内亚大图
多伦多国际电影节原始图片
图4。 GRHL2和PR共同调控参与乳腺发育的靶基因。
A）野生型（WT）T47DS细胞及shRNA介导的GRHL2基因降（shGRHL2）T47DS细胞，在1 nM R5020刺激24小时后，体体RNA测序过程的概览，以及选择GRHL2和PR共调基因的标准。B）对WT和shGRHL2 T47DS细胞的体量RNA测序数据进行热图，该细胞被1 nM R5020刺激，持续4小时或24小时。热图显示了根据（A）中列出的标准选择的298个基因的无监督聚类和表达变化。表达式值以n=3次重复时的z分数表示。NT = 未治疗的剥离血清状态，T = 处理过的状态。C）点阵图，显示对298个选定的GRHL2和PR共调基因进行Go项富集分析。富集分析和图生成使用Clusterprofiler完成[49]。D）qRT-PCR数据条形图，显示WT或shGRHL2 T47DS细胞中，1 nM R5020处理4小时后GRHL2、IGFBP5和TGFB2的平均相对表达。参考基因：YWHAZ。数据点：n=2/3个生物复制体的个别值，以平均重叠变化为对照标准化。P值采用双因子方差分析计算，随后进行未校正费舍尔最低显著差异检验。
https://doi.org/10.1371/journal.pgen.1012088.g004
我们进行了首次探索性分析，以评估由GRHL2和PR共调控的298个基因的潜在临床相关性。为此，通过cBioPortal下载了METABRIC（乳腺癌分子分类国际联盟）队列的临床和转录组数据，该队列包含1980个原发性乳腺肿瘤[45–48]。其中940个肿瘤被归类为PR阴性，1,040个被归类为PR阳性。事实上，分配的PR状态与PGR mRNA表达水平对应（S3A见图）。值得注意的是，PR阴性和PR阳性肿瘤之间的GRHL2表达无差异（S3B图）。
随后，我们计算了GRHL2/PR综合特征评分，并根据中位数将肿瘤分为高特征组和低特征组。Kaplan–Meier分析显示，高特征表达患者的总体生存率显著降低（见S3C图），并经多变量Cox回归（调整年龄和肿瘤分期）证实了这一关联（HR = 1.055,95% CI 1.030–1.080，p = 1.1 × 10 ⁻ ⁵）。 反直觉的是，PR阳性肿瘤的特征评分显著低于PR阴性肿瘤（S3D图）。由于低签名评分与生存率提升相关，我们使用多变量Cox模型及交互项测试了签名的预后影响是否因PR状态而异。相互作用无显著性（HR = 1.038,95% CI 0.976–1.103，p = 0.24），表明较高的特征表达与PR阳性和PR阴性肿瘤的较差结局相关。 由此我们初步得出结论，虽然GRHL2/PR特征与较差预后有关，但这与PR状态无关。然而，重要的是要注意，本分析属于探索性质。原发肿瘤的功能性PR信号难以直接评估，细胞系模型可能无法完全重现肿瘤生物学。因此，还需要进一步验证和分层分析，以进一步评估乳腺癌患者PR/GRHL2评分的预后价值。
染色质环连接GRHL2和PR位点与远端目标基因
尽管我们对三维基因组组织的理解取得了重大进展，但功能上将增强子与其目标基因连接仍具挑战性[50]。在大多数研究中，增强子被分配到最近的基因，尽管实际上33–73%的增强子并不一定调控其最近的基因[51–53]。这很重要，因为PR以及许多其他转录因子经常与距离其真实相关TSSs在30 kb到1 Mb之间的远端增强子结合[54,55]。高分辨率染色质构象捕捉技术——如Hi-C、5C、ChIA-PET和HiChIP——能够识别对转录调控至关重要的长程染色质相互作用[50]。
基于此，我们试图物理连接基因组中的GRHL2和PR位点（由ChIP-seq，见图2）与它们调控的基因（由RNA-seq识别，见图4）。我们推断，如果GRHL2或PR位点参与特定基因的调控，它应当环路到该基因的TSSs。为验证该假设，我们使用了之前发表的PR HiChIP数据集，该数据集使用T47D细胞获得[38]。HiChIP是Hi-C的延伸，通过富集由感兴趣的转录因子或组蛋白修饰结合的DNA相互作用，捕捉蛋白质特异性染色质环。每个染色质环包含两个锚点，分别位于两端，代表通过三维染色质环路被带到接近的相互作用DNA区域。PR HiChIP在R5020刺激30分钟后，捕获了7,076个无刺激PR染色质环，以及9,591个在一个或两个锚点处发生PR染色质环（图5A）。其中仅有987个环重叠，显示PR介导染色质在R5020刺激后30分钟内发生显著重连（图5A）。
缩略图 下载：
PPT幻灯片
巴布亚新几内亚大图
多伦多国际电影节原始图片
图5。 对HiChIP、ChIP-seq和RNA-seq的整合分析揭示了功能性的GRHL2–PR环。
A）维恩图，显示未处理（T0）条件下PR HiChIP环路与30分钟10 nM R5020处理状态（T30）之间的重叠情况。数据重绘（即Zaurin等人[38]B）的被调用环数，甜甜圈图显示了GRHL2和PR调控基因的转录起始位点（TSS）比例，这些位置与先前发表的PR HiChIP锚点重叠[38]。在通过RNA-seq识别的298个GRHL2和PR调控基因中，有79个基因具有与HiChIP锚点重叠的TSS。剩余219个基因的TSS与HiChIP锚点不重叠。C）通过染色质环路可视化GRHL2和PR峰如何汇聚ARF6基因启动子，显示PR ChIP-seq [38]峰、GRHL2 ChIP-se序列[23]峰和PR HiChIP环[38]，直接锚定于GRHL2/PR调控的TSS。锚点按GRHL2和PR占用率着色，如右下角图例所示，没有GRHL2、PR ChIP-seq信号或带注释TSS的锚点被定义为“其他”。基因TSS用灰色条高亮显示。数据在IGV浏览器中进行可视化[39]。D）甜甜圈图，展示了HiChIP[38]锚点占用率，分类为与GRHL2峰值、PR峰值、TSS或这三者的组合重叠。包含的292个锚点（146个环中每个两个）与79个GRHL2的TSS和PR调控基因相关，这些基因与HiChIP[38]锚点重叠。E） 定义为与GRHL2、PR、GRHL2 + PR ChIP-seq峰或其他在146个选定HiChIP [38]环路对对面锚点重叠的锚点频率的可视化表示。这121个环路被选中至少有一个锚点具有PR ChIP-seq峰值。线条的颜色和粗细代表出现频率。
https://doi.org/10.1371/journal.pgen.1012088.g005
接下来，我们将PR HiChIP数据与GRHL2及PR ChIP-seq和RNA-seq数据整合。这里，我们使用了之前发布的 ChIP-seq 数据，而非新生成的 CUT&RUN 数据集，因为 HiChIP 在方法论上与 ChIP 更为相似，因此更有可能有效整合。首先，我们从RNA-seq分析中提取了全部298个GRHL2-PR共调控基因，评估其TSS是否与至少一个HiChIP环的锚点重叠。通过该方法，我们鉴定出79个基因在转录上受GRHL2和PR调控，且在其TSS附近或附近也拥有PR HiChIP环锚点（图5B）。我们共识别出146条直接连接79个GRHL2和PR调控基因的环路（图5B-5C）。这些环路长度可达500kb，大多数跨度为50–100kb（S4A见图）。随后我们想知道GRHL2和PR是否能在这146个环的锚点被探测到。因此，我们对GRHL2和PR ChIP-seq数据进行了比对，以评估它们在每个锚点的占用情况。对于所有146个环路，我们根据是否存在GRHL2和/或PR ChIP-seq峰和/或TSS对相关的292个锚点进行了分类（见图5C，5D）。 在注释锚点中，26%在GRHL2和PR之间共享（~相较整个ChIP-seq数据集富集为两倍，见图2B），其中14%位于或接近TSS。
另有29%仅含有PR峰，其中15%位于或靠近TSS，11%仅含有GRHL2峰，其中2%位于或接近TSS（见图5D）。值得注意的是，21%的环锚属于“其他”类别，意味着它们缺少GRHL2、PR或TSS注释（见图5D）。我们假设这些锚点可能被参与GRHL2和PR靶基因联合调控的其他转录调控因子占据。为探讨这一可能性，我们专门在这些位点进行了基序富集分析（S4B图）。该分析未发现此前与乳房有特异关联的转录因子。然而，我们观察到STAT3的显著富集，这一因子在GRHL2 RIME中也被观察到（图1C），表明STAT因子可能参与GRHL2和PR发挥功能的三维调控情境（S4B图）。
为进一步探讨GRHL2与PR在基因调控中的协同功能，我们分析了它们在PR HiChIP环对向锚点的占有情况（见图5E）。这里，我们只包含了至少在两个锚点中有一个有PR ChIP-seq峰值的环路，因此总共选择了121个环路。其中，~56%至少含有一个锚点同时含有GRHL2和PR ChIP-seq峰，表明GRHL2-PR介导基因调控最常见的方式可能是GRHL2和PR与至少一个调控元件的共结合（见图5E）。尽管如此，GRHL2与PR占有的其他组合也被观察到，表明不同结合GRHL2和PR的元件可以通过三维染色质结构趋同，共同调控基因表达（见图5E，S4C）。 此外，一些PR、GRHL2或GRHL2-PR重叠的峰不仅与基因启动子建立了直接连接，还与额外的GRHL2和PR（以及其他转录因子）结合位点相互作用（S4C见图）。
GRHL2和PR转录共调的整合模型
CTCF和内腭介导的环路已被广泛认可为促进长程增强子-启动子相互作用的关键机制[56]。在我们的RIME中，我们发现GRHL2与多个Cohesin复合组分及相关调控因子相关（S5A图）。此外，公开的CTCF [42]和RAD21 [42]在未处理和30分钟R5020处理条件下的ChIP-seq数据集显示，虽然CTCF结合相对稳定，但RAD21与染色质结合在R5020处理后高度富集（S5B-C 图）。由于TAD边界在R5020存在与否下相对稳定[57]，我们假设部分GRHL2/PR/TSS相互作用由CTCF/Cohesin介导的环路介导，从而在GRHL2–PR增强子与其靶启动子之间的空间接近度中起作用。我们推测，在孕酮存在的情况下，RAD21/Cohesin复合物可能与GRHL2一起被招募到染色质中。
综合所有数据，我们提出了一个由GRHL2和PR共调控基因的模型，在缺乏激素刺激的情况下，GRHL2和PR已存在于细胞核内，并能够物理相互作用（见图6，左侧）。在此条件下，PR基本不结合其基因组靶位点，而GRHL2则与不一定与GRHL2和PR共调控靶基因相关的区域结合，然而，它很可能已经动态且在更低水平上与共享的GRHL2/PR位点结合（图6，左侧）。大多数由任一或两项因子结合的基因组靶点和调控元件尚未接近其各自目标基因的启动子（见图6，左侧）。在孕酮存在或实验环境中，R5020刺激时，核内GRHL2和PR的水平会微妙上升，转录活性PR被招募到GRHL2/PR共享且仅PR结合位点。同时，在孕激素刺激下，GRHL2染色质结合会被强化和重组。
缩略图 下载：
PPT幻灯片
巴布亚新几内亚大图
多伦多国际电影节原始图片
图6。 一个展示GRHL2–PR共调控目标基因转录调控的模型。
GRHL2和PR在特定共调控目标基因的调控机制模型。在缺乏激素（左图）的情况下，GRHL2和PR形成一个复合体，GRHL2动态结合于与GRHL2-PR目标基因无关的区域，同时在更低水平下，PR大多不结合染色质。因此，GRHL2和PR不与其靶引导子相互作用。孕酮刺激（右侧）会触发GRHL2和PR被增强子招募，并形成CTCF/内聚蛋白依赖性和独立染色质环路，将由GRHL2、PR或辅因子共结合或单独结合的远端元件与其目标基因连接起来。
https://doi.org/10.1371/journal.pgen.1012088.g006
除了相互结合外，GRHL2和PR还与多种协同因子结合。这导致局部GRHL2和PR浓度极高，这得益于CTCF/Cohesin依赖性和-非依赖性环路，将远端增强子与靶向启动子连接（图6，右）。虽然超过一半的PR环增强子至少在一个锚点上被GRHL2和PR共结合，但不同的GRHL2或PR结合元素也会在启动子上收敛（见图6右侧）。此外，多个增强子位点——由GRHL2和/或PR及其他转录辅因子结合——通过直接或间接环路与基因启动子紧密结合，从而高效转录参与孕激素驱动乳腺组织发育和生理的基因（图6，右侧）。
讨论
本研究为先驱转录因子GRHL2与类固醇激素受体PR协调转录调控提供了机制框架。通过整合T47D和T47DS细胞在未刺激和R5020刺激条件下的蛋白质组学、转录组学和基因组分析，我们提出了一个GRHL2和PR共调控靶基因的模型，在缺乏激素的情况下，GRHL2和PR形成一个预组装的核复合体，并与其他染色质修饰因子相关（见图1A-D和图6， 左）。在孕酮刺激下，GRHL2和PR在特定增强子处富集，启动激素依赖性的染色质环路，使远端调控元件（或由GRHL2和PR共结合，或由任一因子单独结合）与其目标基因启动子接触，激活对乳腺发育和生理至关重要的转录程序（图6，右侧）).因此，虽然整体核GRHL2蛋白相互作用组在激素刺激下未发生重大变化（见图1E），但这些发现揭示了一种动态的激素响应调控结构，使乳腺细胞基因表达能够精确时空调控。
利用RIME和共免疫沉淀法，我们鉴定PR在血清脱离条件下是GRHL2的孕酮非依赖性相互作用物。虽然RIME涉及有利于染色质相关蛋白的核富集步骤，但免疫沉淀作用于核裂解液，因此同时捕获染色质结合和可溶性核复合物。因此，在没有配体的情况下观察到的PR–GRHL2相互作用，很可能反映了未稳定结合染色质的核复合物。这与已知配体对稳定PR-DNA结合的要求一致。我们提出PR和GRHL2可能在核质内形成预先存在的复合物，这些复合物在配体刺激下能迅速与染色质结合。与此观点一致，R5020处理后GRHL2结合增强并重新分布，表明预形成的PR–GRHL2复合物可能促进GRHL2快速招募到孕激素响应的基因组区。
GRHL2-PR的相互作用也出现在一项对MCF7和T47D细胞进行PR RIME的研究中[35]，但这里显示为孕激素依赖性。尽管两项研究均检测到PR与GRHL2之间的相互作用，但我们的发现在激素依赖性上存在差异。最可能的解释是穆罕默德等人。[35]采用了一种未治疗的状态，涉及含有内源性雌激素和孕酮的全血清培养基，并能模拟生理激素刺激。相比之下，我们的非刺激样本是在剥离血清条件下获得的。此前研究显示，GRHL2可与其他激素受体结合，即内质网[23,25,58]和AR[59]。具体来说，GRHL2增强了内质网和抗逆体依赖的结合及转录活性[25,59]。在前列腺癌细胞中，GRHL2本身是一个AR靶基因[59]，类似于我们观察到GRHL2在乳腺癌细胞中是PR靶点[60]。由于GRHL2在雌激素、雄激素和孕酮信号通路中发挥作用，在多个激素受体同时表达和活跃的细胞中，GRHL2的结合可能具有动态分布。控制这种分布的机制尚不清楚。值得注意的是，我们发现在T47DS细胞中，且在缺乏雌激素和孕酮的情况下，GRHL2优先与PR结合，且这种相互作用在孕激素刺激下得以维持或可能增强。结合上述研究观察，我们假设在雌激素存在下，无论是单独存在还是与低水平孕酮同时存在，GRHL2可能更倾向于与内质网结合而非PR。这共同引发了关于GRHL2的DNA结合活性和相互作用组在激素波动条件下如何调控，以及这种调节如何促进激素响应细胞的转录程序的重要问题。
本研究仅简要探讨了哪些额外的转录因子可能参与GRHL2–PR介导的基因调控。尽管如此，我们在PR-、GRHL2-和GRHL2-共享结合位点的RIME和基序分析中，仍鉴定出若干转录因子及其家族。例如，FOXA1在GRHL2、PR和GRHL2–PR共享区域的全基因组分析中，成为富集最强的基序之一（S1A图），同时也是我们PR CUT&RUN数据中富集基序中的典型，这与其在成熟腔体内的核心作用一致[43,61–63]。有趣的是，FOXA1的耗竭被报道会增加增强子位点的PR结合[64]，表明FOXA1在某些情况下可能与PR竞争增强子占有率。综合来看，这些观察表明，虽然GRHL2和FOXA1在某些环境下可能合作，但GRHL2与PR的协调活性很可能在很大程度上独立于FOXA1发生。同样，在我们的RIME分析中检测到了GATA3和TRPS1，且在ChIP-seq数据中，GATA基序在仅PR、仅GRHL2和GRHL2–PR共享区域中得到丰富。鉴于GATA3与内质网表达和功能相关[19,20]，它可能在协调内质网/PR活性方面扮演类似GRHL2的角色。最后，STAT1、STAT3和STAT6被鉴定为GRHL2的相互作用体，且在ChIP-seq数据中，STAT结合基序在仅PRs、仅GRHL2及GRHL2-PR重叠位点富集。IL/STAT 信号此前已被关联于内质网和 PR 通路[65,66]，但据我们所知，本研究是首个将 GRHL2 与 STAT 信号联系起来的证据，值得进一步探讨其潜在的功能相互作用。
我们的CUT&RUN分析显示，当孕酮存在时，GRHL2染色质结合会重新分布并增加。此前未曾报道，但这与GRHL2作为直接PR靶点[60]以及先前研究显示雌激素治疗能促进全基因组GRHL2结合增加[58]相符。有趣的是，我们发现R5020处理后检测到的GRHL2 CUT&RUN峰（未治疗条件下检测不到）与非激素刺激条件下ChIP-seq识别的GRHL2位点重叠（S1D见图）。这种差异可能由原始ChIP-seq实验中残留的激素活性或方法学差异解释：与ChIP-seq不同，CUT&RUN不涉及交联，因此更可能捕获稳定的DNA-蛋白质相互作用。短暂、较弱或间接的相互作用，如动态转录因子如GRHL2和PR，可能只有在稳定（如激素治疗）后才能通过CUT&RUN检测到，而ChIP-seq则可能更容易捕捉这些相互作用。这些方法学和生物学差异也可能解释为何我们的CUT&RUN数据中识别出的GRHL2和PR峰数量比重新分析的ChIP-seq数据集少近两个数量级（见图3B与图2B）。
归根结底，确定单个增强子的精确功能并准确将其与目标基因连接仍具挑战性。这一困难主要源于增强子的位置，它们通常距离其调控的基因相当远，同时它们能够绕过附近和夹杂的基因。尽管如此，绘制增强子与靶基因关系对于理解增强子在正常生物学和疾病中的功能至关重要。在缺乏单独实验验证的情况下，基于染色质构象的方法目前是预测增强子-启动子相互作用的最有效方法。因此，我们利用PR HiChIP数据将GRHL2和/或PR位点与其目标基因连接起来。虽然这种方法比将峰值分配到最近基因更能提供更高的目标分配置信度，但也存在局限性。值得注意的是，我们使用的PR HiChIP数据集是在孕激素刺激后的早期时间点（即30分钟）生成的。虽然这使得最早的GRHL2–PR共调靶点被识别，但额外的时间点将捕捉更广泛的相互作用动态范围，增加可分配靶点数量，并为PR介导的增强子-启动子环路的时间动态提供见解。此外，由于该数据集以PR为中心，它无法捕捉那些不直接涉及PR但可能收敛于相同启动子的GRHL2介导染色质环。因此，我们可能低估了GRHL2调控影响的范围以及GRHL2–PR共调控靶基因的整体分布。然而，分开PR和GRHL2 HiChIP数据集也不理想，因为它们无法直接检测PR和GRHL2重叠锚点。遗憾的是，目前尚未开发出测量两种转录因子蛋白质导向基因组结构的方法。
总之，本研究通过整合基因组学、转录组学和蛋白质组学数据，拓展了我们对乳腺上皮中孕酮信号调控景观的认识。我们发现了GRHL2与PR之间此前未被发现的合作关系，通过动态染色质结合和三维基因组组织协调激素响应基因表达。我们的模型假设，在缺乏激素的情况下，GRHL2和PR会形成复合物，但在这种条件下，它们并不能稳定地结合染色质。孕激素刺激招募GRHL2-PR复合物到增强子，随后形成染色质环，将远端元素与目标基因启动子连接起来。GRHL2、PR或辅因子的共结合或个体结合随后激活关键转录程序。该模型为理解GRHL2–PR介导的基因调控提供了广泛的框架。然而，我们发现每个目标基因最终都由一组独特的远端元素单独或联合结合，这些因子由GRHL2、PR及其他转录因子结合，这些因子环路到其启动子。我们的综合分析强调了这些调控相互作用的复杂性和基因特异性，展示了仅仅两个转录因子相互作用即可产生的复杂性。
研究的局限性
虽然我们的多组学方法提供了激素无关性物理相互作用的证据，支持GRHL2和PR在孕激素刺激下的协调增强子占有，但仍需承认若干局限性。首先，尽管我们展示了PR与GRHL2的共居、染色质环路以及协调转录调控，但GRHL2调节PR依赖增强子活性的具体分子机制仍未解决。特别是GRHL2究竟主要作为先驱因子、共调控因子的支架，还是参与环状形成的结构成分，以及GRHL2是否影响PR结合动力学，需要进一步的机制分析。其次，大部分分析是在T47D（S）细胞中进行的，这些细胞过度表达PR。尽管该细胞系是极少数对PR反应的细胞系之一，能够受控地探究GRHL2/PR的交叉调控，但它并未反映内源性化学计量或生理调控。因此，进一步验证我们在其他细胞系和乳腺（癌症）模型中的发现，对于评估所提出调控机制的普遍性和生物学相关性将非常重要。第三，由于目前只有一种功能良好的GRHL2抗体可用，该抗体被用于所有实验，包括RIME、Western blots和CUT&RUN分析，以及我们重新分析的之前生成的ChIP-seq数据集。尽管经过精心筛选并广泛使用，我们未能通过替代的GRHL2抗体确认数据，也无法正式排除与GRHL1的交叉反应性。最后，仅在mRNA水平评估了GRHL2/PR共调控基因的功能验证。虽然转录组变化稳健且可重复，但由于技术限制，包括缺乏合适的抗体，无法对关键靶点如IGFBP5和TGFB2进行蛋白质级验证。因此，转录变化在蛋白质丰度和下游细胞表型变化中的影响程度仍有待确定。
材料与方法
细胞培养
人类T47DS乳腺癌细胞（由荷兰乌得勒支胡布雷希特研究所Stieneke van den Brink博士慷慨捐赠）和HEK293TN细胞（System Biosciences，#LV900A-1）常规培养在含有GlutaMAX（Gibco，#11584516）的Dulbecco改良鹰培养基（DMEM），并补充10%胎儿牛血清（FBS）（Thermo Fisher Scientific，#11573397）。细胞每3-4天以1：10比例分割，并常规检测支原体。处理后，T47DS细胞在含GlutaMAX（Gibco，#11584516）的DMEM中培养，辅以5%活性炭剥离胎牛血清（Thermo Fisher Scientific，#A3382101）24小时，随后在指示时间内刺激1 nM R5020（Perkin Elmer，#NLP004005MG），同样在剥离血清条件下进行。
T47DS GRHL2 敲击线的生成
为产生慢病毒，5× 10⁶ HEK293TN细胞种子于10厘米的培养皿中。次日，细胞被转染3微克包装载体pCMVDR8.2（Addgene，#8455）、3微克RSV-rev（Addgene，#12253）、3微克VSV-G（Addgene，#12259）和8微克pLKO.1 GRHL2 shRNA载体（RNAi联盟，TRCN0000015812;阿姆斯特丹联合卫理公会Peter Stroeken慷慨赠送）。24小时后，培养基进行更新。转染后48小时采集病毒上清液，通过0.45微米滤纸过滤，并以1：2比例稀释。T47DS细胞在聚苯（1：2,000;默克米利普尔，#TR-1003-G）存在下被病毒上清液感染。孵育24小时后，细胞被切割并用普罗霉素（1 μg/mL，Thermo Fisher Scientific，#A1113803）选拔，以产生稳定的GRHL2敲低系。
内源性蛋白快速IP-质谱（RIME）
RIME分析按照Mohammed等人之前描述的方式进行[31]。简要，6x107每种条件下，T47DS 通过向培养基中加入甲醛（Thermo Fisher Scientific， #28908）至最终浓度为1%，交联8分钟。反应通过将甘氨酸加入至最终浓度0.1 M来淬火。细胞被用冰冷的PBS洗涤两次，辅以蛋白酶抑制剂（Sigma-Aldrich，#P8340,1：500），并通过刮除板块收集。随后通过离心法将细胞沉淀为2,000克，浸泡3分钟，浸泡在4°C，并使用溶解缓冲液LB1（50 mM HEPES-KOH，pH 7.5,140 mM NaCl，1 mM EDTA，10%（vol/vol）甘油，0.5%（vol/vol）天然-40,0.25%（vol/vol）Triton X-100）。随后在4°C旋转5分钟时，再次对LB2进行裂解（10 mM Tris-HCL（pH 8.0）、200 mM NaCl、1 mM EDTA和0.5 mM EGTA）。 随后将样品重新悬浮于LB3中（10 mM 三盐酸（pH 8.0）、100 mM NaCl、1 mM EDTA、0.5 mM EGTA、0.1%（重量/体积）脱氧胆酸钠和0.5%（体积/体积）N-月烯酸盐），并分成三根独立的Eppendorf管，在Bioruptor pico中进行超声波处理。（Diagenode）在4°C下使用30秒的开关循环，持续10个周期。再次将超声波样本合并，加入Triton X-100至最终1%体积，并通过离心清除裂解液。与此同时，Dynabeads（蛋白A、Invitrogen、#10001D）在含有5 mg/ml BSA的PBS中洗涤了四次。在室温下，将5 μg GRHL2抗体（Sigma Aldrich，#HPA004820）和IgG（Santa Cruz，#sc-2027X，作为阴性对照）结合在PBS/BSA溶液中，在室温下共轭1小时。通过超声核裂解液与抗体共轭的珠子混合，并在4°C下旋转培养过夜。次日，用RIPA缓冲液（50 mM HEPES（pH 7.6）、1 mM EDTA、0.7%（重量/体积）脱氧胆酸钠、1%（体积/体积）NP-40和0.5百万LiCl）洗涤，共洗涤十次。对于每个实验条件，三个独立处理的样本被并行处理，代表用于评估可重复性的重复样本。
此后，阿姆斯特丹大学斯瓦默丹生命科学研究所生物分子质谱实验室负责处理和分析。简而言之，输入样本的处理方式如Hughes等人[67]所述。蛋白质浓度通过Pierce BCA蛋白质检测法（Thermo Fisher Scientific， #23227）定量，按照制造商的方案进行，所有样品均一次性还原并烷基化。根据Mohammed等人[31]，拉下样品被珠状消化。肽样品使用Ultimate 3000 RSLCnano UHPLC系统（德国格默林根Thermo Fisher Scientific）与TIMS-TOF Pro质谱仪（德国不来梅布鲁克）进行分析。原始数据使用MaxQuant（版本2.6.2.0）处理，胰蛋白酶/P被指定为消化酶，允许最多遗漏两个切割。半胱氨酸的氨甲酰甲基化被设定为固定修饰，甲硫氨酸的氧化则为可变修饰。光谱与人类单蛋白蛋白组数据库进行了检索。MaxQuant IBAQ输出值用于Perseus（版本2.1.3.0）进行下游分析。潜在污染物、仅通过携带一个或多个修饰氨基酸的肽鉴定的蛋白质，以及从诱饵序列中识别出的蛋白质被过滤掉。取值采用Log2变换，且每个实验组缺失一个值的行被丢弃。其他NaN值被从正态分布中替换，三次技术重复实验利用两样本学生t检验和基于置换的假发现率（FDR）修正以识别多重测试中不同条件间表达的蛋白质。采用了FDR<0.05的显著阈值。诱饵蛋白GRHL2具有2折叠富集为3.3且为-Log10（padj）2.2。原始和处理后的RIME数据通过以下渠道公开：https://osf.io/9uqsw/。
共免疫沉淀
在T47DS细胞中共免疫沉淀GRHL2，利用约3个×10⁸细胞完成。细胞在皿上直接用含有蛋白酶抑制剂（Sigma-Aldrich，#P8340,1：500）清洗一次，然后通过刮擦采集。颗粒化细胞被重新悬浮在溶解缓冲液中（50 mM 三盐酸（pH 7.40）、5 mM EDTA、0.25% Triton X-100、10% 甘油、100 mM NaCl）中，并在4°C下培养30分钟，并轻柔旋转。裂解液通过离心法在2000×克、4°C下20分钟清除。 上清液的一小块被保留为整个裂解液控制的输入。剩余裂解液在4°C下与5 μg GRHL2抗体（Sigma-Aldrich，#HPA004820）轮流孵育。次日早晨，加入50微升预平衡的Dynabeads蛋白A（Invitrogen，#10001D），并在4°C下旋转样品1小时。 珠子用裂解缓冲液洗涤三次，结合蛋白通过在洗脱缓冲液中煮沸（50%裂解缓冲液，50%Laemmli缓冲液;Sigma-Aldrich，#38733）在95°C下持续5分钟。随后通过西部印迹分析了洗脱后的蛋白质。
西部污点
西方印迹法如前所述进行[68]。简而言之，一半的免疫沉淀或输入样本被装入10%的SDS-PAG凝胶上。蛋白质通过转印涡轮转移系统（Bio-Rad）转移到0.2微米的硝化纤维素膜上，并用1：1稀释的TBS和Odyssey阻断缓冲液封闭（LI-COR Biosciences， #927–50100）。膜在4°C下过夜孵育，稀释原级抗体于阻断缓冲液中，补充0.1% Tween-20：抗PR（1：1,000，Thermo Fisher Scientific，#MA5–16393，识别PR-A和PR-B）和抗GRHL2（1：2,000，Sigma-Aldrich，#HPA004820）。次日，膜在补充0.1% Tween-20的TBS中洗涤，并在RT下与稀释1：20,000的次级抗体及0.1% Tween-20在TBS中孵育1小时：IRDye 680LT（LI-COR，#926–68022）或IRDye 800CW（LI-COR，#926–32211）。信号检测使用奥德赛Fc成像系统（LI-COR生物科学）完成。
RNA分离、文库制备及RNA测序分析
RNA的分离、处理和RNA测序分析均如前所述[69]。总之，70万个T47DS WT或GRHL2敲低细胞（稳定shRNA）被植入含有DMEM + GlutaMAX（Gibco，#11584516）的6孔板中，并辅以5%含炭的胎牛血清（Thermo Fisher Scientific，#A3382101 年）。电镀后24小时，培养基进行更新，细胞再用1 nM R5020或乙醇（载体对照）处理24小时。按照制造商说明，使用RNeasy Mini Kit（Qiagen，编号#74104）并进行柱上DNA酶消化（Qiagen，RNase-Free DNase Set，编号#79254）进行RNA分离。
为文库制备，使用NEBNext Poly（A）mRNA磁分离模块（新英格兰生物实验室）对1微克总RNA进行了poly（A）选择。RNA测序文库使用NEBNext Ultra II定向RNA文库制备套件和NEBNext多重寡核（Dual Index 引物对;新英格兰生物实验室），遵循制造商的规范。使用配备安捷伦D1000屏幕磁带的2200 TapeStation系统（安捷伦科技）评估了图书馆规模分布。定量工作使用NEBNext库定量套件，在QuantStudio 3实时PCR系统（Thermo Fisher Scientific）上完成。库通过NextSeq 500/550高输出套件v2.5（75周期）在NextSeq 550系统（Illumina）上进行序列（75位元对应单端）。所有图书馆的准备和测序均由阿姆斯特丹大学斯瓦默丹生命科学研究所（Swammerdam Institute for Life Sciences）荷兰基因组服务与支持提供者MAD负责。
原始的FASTQ文件在银河服务器上处理。质量控制使用MultiQC [70]进行，随后用Trimmomatic[71]通过策划的适配器列表对过度代表序列进行裁剪。通过HISAT2对截断读序列比对到人类参考基因组（GRCh38.p14）[72]。映射质量通过SAMtools统计评估，并用MultiQC总结。读取计数使用HTSeq计数[73]获得，并在RStudio（版本2023.06.1）中使用DESeq2进行差异基因表达分析[74]。这些数据已以编号GSE291778存放于NCBI GEO。通过 https://osf.io/9uqsw/ 以下网站，298个GRHL2和PR共调控基因，以及79个由GRHL2和PR转录调控且在其TSS附近拥有PR HiChIP环锚点的基因的Log2fold变异列表。通过Clusterprofiler R包的enrichGO（）函数对选定的PR和GRHL2调控基因进行Go项富集[49]。
RNA分离与qRT-PCR
RNA分离和qRT-PCR的操作如前所述[68]。简而言之，按照制造商的方案，使用TRIzol试剂（Invitrogen，#15596018）从T47DS细胞中提取了总RNA。分离的RNA被RQ1 DNase（Promega，#M6101）处理以去除基因组DNA污染。cDNA合成采用SuperScript IV逆转录酶（Invitrogen，#18090200）和随机六聚体（Invitrogen，#N8080127），并加入了RiboLock RNase抑制剂（ThermoFisher，#EO0328）。所得的cDNA样本在qRT-PCR前被稀释了10倍。定量实时PCR使用5台HOT FIREPol EvaGreen qPCR Mix Plus（ROX）（Solis Biodyne，#08-24-00008）在QuantStudio 3实时PCR系统上完成。引物序列列于表1。相对表达水平采用ΔΔCt方法计算，并归一化至YWHAZ[75]及未处理对照样本。
缩略图 下载：
PPT幻灯片
巴布亚新几内亚大图
多伦多国际电影节原始图片
表1。 用于qRT-PCR的引物。
https://doi.org/10.1371/journal.pgen.1012088.t001
CUT&RUN 低容积尿素（LoV-U）
CUT&RUN LoV-U 的执行方式如 Zambanini 等人所述。[76]，并进行了以下修改。每个样本约采集50万个T47DS细胞，使用0.25%胰蛋白酶，并在核提取缓冲液中洗涤三次细胞（20 mM HEPES-KOH（pH 8.2）、10 mM KCl、0.5 mM spermidine、0.05% IGEPAL、20% 甘油和罗氏完全蛋白酶抑制剂无EDTA）中分离细胞核。核颗粒被速冻在异丙基腔室中，并以–80°C储存，等待进一步加工。核被解冻，在核提取缓冲液中洗涤一次，随后结合于平衡的磁性ConA琼脂糖珠（抗体在线，#ABIN6952467）。培养后，核珠复合物在洗涤缓冲液（20 mM HEPES（pH 7.5）、150 mM NaCl、0.5 mM spermidine和罗氏完全蛋白酶抑制剂 EDTA-Free，0.025% 地微素）中洗涤5分钟，然后转移到PCR管中。加入抗体（抗PR（1：100，细胞信号，#8757S）、抗GRHL2抗体（1：100，Sigma-Aldrich，#HPA004820）或兔IgG同型对照（1：100，Invitrogen，#100500C））加入洗涤缓冲液中，并在4°C旋转器上隔夜孵育。次日，样品用洗涤液洗涤五次，然后重新悬浮于pAG-MN缓冲液（含120 ng/样品pAG-MN）中，并在旋转器上以4°C培养30分钟。经过五次洗涤后，消化启动，将珠子重新悬浮在补充2 mM CaCl₂的洗涤缓冲液中，并在室温下培养5分钟，随后在4°C下再培养25分钟。 通过添加250 mM EDTA/EGTA混合物，该反应被阻止。通过加入5 M NaCl并在37°C下孵育30分钟，开始释放片段。收集上清液后，将小珠重新悬浮于1个×尿素缓冲液中（100 mM NaCl，2 mM EDTA，2 mM EGTA，0.5% IGEPAL，8.5M 尿素），进行第二次释放步骤。在室温下30分钟后，尿素释放液与初始上清液结合。样品先用SDS和蛋白酶K处理，随后进行酚：氯仿：异戊醇萃取和乙醇沉淀。文库在Illumina NextSeq 550平台上采用36碱基对序端读段测序，深度为每样本500万至1500万次。
CUT&RUN 数据分析
读取质量通过fastQC评估[77]。读取序列通过bbmap bbdud [78]裁剪，以去除适配器和多重[AT]、[G]和[C]重复序列。读段与hg38基因组配对，配对了蝴蝶结2[79]，选项为：–local –very-sensitive local – no-unal –no-mixed -no-discordant –phred33 –dovetail -I 0 -X 500。使用Samtools套件[80]来移除重复和错误配对的读取。Bedtools [81] 用于从 bam 文件中移除映射到 CUT&RUN hg38 嫌疑人列表 [82] 的读取。床图是利用Bedtools genomecov的配对端模式创建的。峰值通过MACS2[83]进行调用，针对窄峰的IgG对照，选项为-f BAMPE和-p 1e-3。CUT&RUN数据已以GSE307203号存入NCBI GEO。
ChIP-seq数据集的再分析
来自PR [38]的原始ChIP-seq数据文件（Control;SRX11374768，并处理了1 nM R5020;SRX11374766）和GRHL2[23]（两个复制体;SRX5350536，SRX5350537）数据集从SRA服务器下载。读取质量使用fastqc[77]（版本0.11.9）评估，随后用Trimmomatic修剪过代表序列适配器和PCR引物[84]。修剪后，读组与hg38基因组与蝴蝶结[79]比对，选项为：局部、极敏感、局部、无一元、无混合、无不和谐、燕尾榫、-I、0、-X500。Samtools [80] 用于将 sam 文件转换为 bam 文件，修复配对错误的配对，并删除重复文件。Bedtools [81] 用于移除映射到 hg38 黑名单区域的读段[85]。可用片段的最终读取计数是从过滤和去重的 bam 文件中确定的。床图是用Bedtools genomecov的配对端模式创建的。在 IGV 中观察到床抓 [39]。为了峰值调用、可视化和信号图，复制的bam文件与SAMtools合并为单一文件。峰值通过MACS2[83]调用，狭窄峰值则有-f BAMPE和-p 1e-3。deepTools [86] 用于将 bam 文件转换为规范化的 BigWig 文件（bamCoverage 使用 -RPGC 选项和 -e 扩展读取至片段长度）。大人物被用IGV形象化;图中显示的轨迹是两个生物复制（GRHL2）或单次复制（PR）合并，归一化为每个基因组覆盖的读段数，并按因子进行尺度化。
下游分析
对于ChIP-seq和CUT&RUN信号强度，均使用deepTools生成了热图和信号剖面[86]。峰值重叠使用床工具计算[81]，要求至少1碱基对重叠。维恩图使用Venndiagram R软件包创建，基因组注释则使用ChIPseeker [40,41] R软件包完成。使用HOMER[44]进行了基序丰富分析，选项为-size 200和-mask。处理了来自R5020刺激T47D细胞的PR HiChIP数据（Zaurin等人）。[38]，GEO注册号：GSM5425945）以.bedpe格式下载，并与549个通过RNA-seq调控的PR和GRHL2基因的TSS区域重叠[81]。选择含有HiChIP锚点的TSS区域进行进一步分析。从ChIPatlas检索了R5020刺激的H3K27ac [42]（SRX22674023）、RAD21[42]（SRX22674036）和CTCF [42]（SRX22674025）的峰值调用ChIP-seq数据集，以及siControl（SRX23397061）和siGRHL2（SRX23397063）的ATAC-seq数据集[43][43]。
临床数据分析
原发性乳腺肿瘤的基因表达和临床数据通过cBioPortal从METABRIC（乳腺癌分子分类国际联盟）队列获取 [45–48]。去除了无基因注释的探针，对于具有多个探针的基因，保留了样本间变异最大的探针。合并了样本和患者层面的临床数据。仅纳入了同时具有临床和表达数据的肿瘤，最终数据集为1,980名患者，用于生存分析。由GRHL2和PR共调控的298个基因（如图4所示）合并为基因签名，使用Hacksig [88]R软件包计算每个肿瘤特征的综合特征评分。上调和下调基因分别评分并合并得出总特征评分。评分在患者间标准化（z评分），高特征组和低特征组以中位数为界限定义。PGR GRHL2的表达水平从表达矩阵中提取用于下游分析，并绘制箱形图比较PR阳性和PR阴性肿瘤间的基因和特征表达。统计显著性通过Wilcoxon秩和检验进行评估。存活数据使用Survival [89,90]和Survminer [91] R软件进行分析。在全队列中，针对高特征与低特征肿瘤生成了Kaplan–Meier生存曲线。存活差异通过对数秩检验进行评估。使用多变量Cox比例风险回归模型评估GRHL2/PR特征评分与总体生存期之间的关联，并调整诊断年龄和肿瘤分期。还测试了交互模型，以评估特征在PR阳性和PR阴性肿瘤间的预后影响是否存在差异。
支持信息
通过CUT&RUN识别的R5020诱导GRHL2结合位点与GRHL2 ChIP-seq序列匹配。
显示1/5：pgen.1012088.s001.tif
跳转到图分享导航
抱歉我们无法加载您的数据。
1 / 5
下载
图格分享
第一季 图。 通过CUT&RUN识别的R5020诱导GRHL2结合位点与GRHL2 ChIP-seq序列匹配。
A）通过HOMER基序分析确定的所有1 nM R5020刺激PR峰、所有未处理的GRHL2峰或GRHL2-PR共享峰中，前五个被确定富集的转录因子基序[44]。B）维恩图，显示4小时1纳米R5050刺激的GRHL2与PR切割与运行峰值的重叠。如果峰重叠至少1个碱基对，则视为重叠。C）两个PR和GRHL2重叠的CUT&RUN峰的代表性例子。数据在IGV浏览器中进行可视化[39]。NT = 未治疗。D）热图显示PR R5020处理后与GRHL2在未处理及4小时1 nM刺激条件下，PR R5020与GRHL2在仅PR、仅GRHL2和GRHL2-PR共享ChIP-seq峰的CUT&RUN信号。
https://doi.org/10.1371/journal.pgen.1012088.s001
（TIF）
第二季 图。 验证直接GRHL2-PR靶基因。
A）对野生型（WT）和shRNA介导的GRHL2敲低（shGRHL2）T47DS细胞进行Western blot，刺激1 nM R5020，持续4小时。展示了三个独立的生物复制体。ACTIN被用作加载控制。B）条形图，显示（A）中西部印迹中GRHL2蛋白在ACTIN上的相对表达。个体数值在未处理的WT（对照）上进行归一化。数据点：n=3个生物复制的个体值，表现为均值折叠变化，归一化为对照。P值采用双因子方差分析计算，随后进行未纠正费舍尔最低显著差异检验。C）对未处理（NT）或用1 nM R5020刺激24小时的WT和shGRHL2 T47DS细胞中，所有在整体RNA序列中表达的基因进行主成分分析（PCA）。每个点代表一个复制品;每个组包含 n = 3 个复制体。
https://doi.org/10.1371/journal.pgen.1012088.s002
（TIF）
第三季 图。 高GRHL2/PR调控的基因表达与乳腺癌患者的总体生存率降低有关。
A-B）箱型图显示了PGR （A） 和GRHL2 （B） mRNA表达（log2归一化）在METABRIC队列中按PR状态分层分布。单个肿瘤以抖动点表示。C）基于中位GRHL2/PR特征评分，将METABRIC肿瘤分层为高特征组和低特征组进行Kaplan–Meier分析。高特征表达（红色）患者整体生存率显著较低表现（蓝色）差（对数秩检验，P < 0.001）。D）显示METABRIC队列中GRHL2/PR特征评分按PR状态分层分布的箱型图。单个肿瘤以抖动点表示。
https://doi.org/10.1371/journal.pgen.1012088.s003
（TIF）
第四季，图。 GRHL2或PR结合增强子可以通过三维染色质环路收敛，共同调控基因表达。
A）146个PR HiChIP[38]环的环径分布密度图，这些环直接连接由RNA-seq确定的GRHL2/PR调控TSS。环路大小以千基（kb）表示。B）选择被认定为富集于不存在GRHL2峰、PR峰或调控TSS锚点的转录因子基序，被定义为“其他”。使用HOMER进行了基序富集分析[44]。C）可视化显示单个非重叠的GRHL2和PR峰，以及通过染色质环路收敛到一个PR峰的ARID5B启动子，显示PR ChIP-seq [38]峰、GRHL2 ChIP-seq [23]峰和PR HiChIP环[38]。灰色条线突出显示ARID5B TSS。橙色条纹突出了PR和GRHL2的各个峰值。数据在IGV浏览器中进行可视化[39]。
https://doi.org/10.1371/journal.pgen.1012088.s004
（TIF）
S5图。 GRHL2与内聚复合体成员相互作用。
A）火山图，展示激素耗竭条件下GRHL2 RIME与IgG对照组的结果。每个灰点表示质谱中识别的单一蛋白质。灰色虚线表示Log2FC（-3,3）和-Log10（p值）截断值（0.05）2,325个通过这些标准的蛋白质，被鉴定为GRHL2相互作用物。红色高亮点表示已知的内聚蛋白亚基，即与GRHL2显著相互作用的负荷和释放因子。B-C）维恩图显示T47D细胞中未处理与30分钟R5020处理的CTCFChIP-seq峰[42]（B）或未处理与30分钟R5020处理的RAD21 ChIP-seq峰[42]（C）之间的重叠情况。对ChIP-Atlas数据（即称为峰值）的重新分析。如果峰重叠至少1个碱基对，则视为重叠。
https://doi.org/10.1371/journal.pgen.1012088.s005
（TIF）
致谢
我们感谢阿姆斯特丹大学斯瓦默丹生命科学研究所生物分子质谱实验室的Gertjan Kramer及其他成员在质谱分析方面的支持。我们还感谢Selina van Leeuwen及MAD：荷兰基因组学服务与支持机构、阿姆斯特丹大学斯瓦默丹生命科学研究所的其他成员，提供测序服务。感谢发育、干细胞与癌症生物学（DSCCB）组的同事以及斯瓦默丹生命科学研究所细胞与系统生物学主题的其他同事，在项目期间给予了富有成效的讨论和反馈。我们要感谢坎图实验室所有成员在我们CUT&RUN实验中的指导。我们特别感谢我们的实习硕士生Jeltje Rommens，他在识别GRHL2和PR调控基因方面提供了初步分析和工作流程设置。
参考文献
1.克莱姆SL、希波尼Z、格林利夫WJ。染色质可及性与调控表观基因组。国家牧师热内。2019;20(4):207–20.PMID：30675018
查看文章PubMed/NCBI谷歌学术
2.Ravasi T、Suzuki H、Cannistraci CV、片山S、Bajic VB、Tan K等。小鼠与人类组合转录调控图谱。细胞。2010;140(5):744–52.PMID：20211142
查看文章PubMed/NCBI谷歌学术
3.费多罗娃 E， Zink D. 核结构与基因调控。生物物理学报。2008;1783(11):2174–84.PMID：18718493
查看文章PubMed/NCBI谷歌学术
4.巴尔德瓦杰·N，扬·K-K，格斯坦·MB。对多样调控网络的层级分析显示，中层协作的趋势一致。美国国家科学院院刊 2010年;107(15):6841–6.PMID：20351254
查看文章PubMed/NCBI谷歌学术
5.金J、崔M、金J-R、珍熙、金VN、赵K-H。人类基因调控网络中转录因子的共调控机制。核酸研究 2012;40(18):8849–61.PMID：22798495
查看文章PubMed/NCBI谷歌学术
6.诺丁·A、赞巴尼尼·G、埃纳尔·约纳森·M、韦斯·T、范德格里夫特Y、帕杰拉·P等。构建小鼠发育过程中转录因子结合图谱，识别出流行的调控区域。发展。2025;152（6）:d ev204311。PMID：40013513
查看文章PubMed/NCBI谷歌学术
7.更富勒。类固醇受体超家族：多样性机制。FASEB期刊。1991.
查看文章谷歌学术
8.Frigo DE， Bondesson M， Williams C. 核受体：从分子机制到治疗。生物化学论文。2021;65(6):847–56.PMID：34825698
查看文章PubMed/NCBI谷歌学术
9.布里斯肯 C，帕克 S，瓦斯 T，莱登 JP，奥马利 BW，温伯格 RA。乳腺发育中上皮孕酮受体在旁分泌的作用。美国国家科学院院刊，1998年;95(9):5076–81.PMID：9560231
查看文章PubMed/NCBI谷歌学术
10.Brisken C， Scabia V. 孕酮90年：正常乳腺中的孕酮受体信号及其对癌症的影响。J Mol 内分泌醇。2020;65（1）：T81–94。PMID：32508307
查看文章PubMed/NCBI谷歌学术
11.阿塔卡·D、奥阿德·P、康斯坦丁·C、拉斯洛·C、贝勒特·M、沙姆塞丁·M等。分泌蛋白酶Adamts18将激素作用与乳腺干细胞生态位的激活联系起来。国家公社。2020;11(1):1571.PMID：32218432
查看文章PubMed/NCBI谷歌学术
12.巴特利特近端锋，埃文斯·I，琼斯·A，巴雷特·JE，哈兰·S，赖塞尔·D等。抗孕激素能减少年轻健康女性乳腺组织中的表观遗传场癌变。基因组医学 2022;14(1):64.PMID：35701800
查看文章PubMed/NCBI谷歌学术
13.扎雷特，堪萨斯州，卡罗尔，JS。先驱转录因子：建立基因表达能力。基因发育 2011;25(21):2227–41.PMID：22056668
查看文章PubMed/NCBI谷歌学术
14.约兹维克，卡罗尔，JS。先驱因素在激素依赖性癌症中存在。纳特·雷夫·癌症。2012;12(6):381–5.PMID：22555282
查看文章PubMed/NCBI谷歌学术
15.乌尔塔多·A，霍尔姆斯·KA，罗斯-因尼斯·CS，施密特·D，卡罗尔·JS。FOXA1是雌激素受体功能和内分泌反应的关键决定因素。纳特·热内。2011;43(1):27–33.PMID：21151129
查看文章PubMed/NCBI谷歌学术
16.卡罗尔·JS、刘XS、布罗茨基AS、李W、迈耶CA、萨里·AJ等。雌激素受体结合的染色体全域定位显示，需要叉头蛋白FoxA1进行长期调控。Cell。2005;122(1):33–43.PMID：16009131
查看文章PubMed/NCBI谷歌学术
17.穆罕默德·H、德桑托斯·C、塞兰杜尔·AA、阿里·HR、布朗·GD、阿特金斯·A等。内源性纯化揭示了GREB1作为关键的雌激素受体调控因子。细胞报告 2013;3(2):342–9.PMID：23403292
查看文章PubMed/NCBI谷歌学术
18.约兹维克·KM，切尔努欣I，塞兰杜尔AA，纳加拉詹·S，卡罗尔·JS。FOXA1通过招募甲基转移酶MLL3，将H3K4单基化导向增强子。细胞报告 2016;17(10):2715–23.PMID：27926873
查看文章PubMed/NCBI谷歌学术
19.Eeckhoute J， Keeton EK， Lupien M， Krum SA， Carroll JS， Brown M. 正向交叉调控环将GATA-3与乳腺癌中雌激素受体α表达联系起来。癌症研究 2007年;67(13):6477–83.PMID：17616709
查看文章PubMed/NCBI谷歌学术
20.马丁·EM，奥兰多KA，横堀K，韦德宾夕法尼亚。雌激素受体/GATA3/FOXA1转录网络：乳腺癌的经验教训。Curr Opin Struct Biol. 2021;71:65–70.PMID：34225008
查看文章PubMed/NCBI谷歌学术
21.里斯·RM，哈里森 MM，阿拉里德·ET。《颗粒头样蛋白2：激素依赖性癌症与表观遗传学的新兴作用》。内分泌学。2019;160(5):1275–88.PMID：30958537
查看文章PubMed/NCBI谷歌学术
22.郑C、高艾伦、刘T、Solodin NM、Meyer MB、Salem K等。GRHL2升高赋予ER阳性乳腺癌细胞的可塑性。癌症（巴塞尔）。2024;16(16):2906.PMID：39199676
查看文章PubMed/NCBI谷歌学术
23.Chi D、Singhal H、Li L、Xiao T、Liu W、Pun M 等。雌激素受体信号在乳腺肿瘤发生过程中被重新编程。2019年美国国家科学院院刊;116(23):11437–43.PMID：31110002
查看文章PubMed/NCBI谷歌学术
24.Wang Z、Coban B、Wu H、Chouaref J、Daxinger L、Paulsen MT 等。腔腔乳腺癌中由GRHL2控制的基因表达网络。细胞通讯信号。2023;21(1):15.PMID：36691073
查看文章PubMed/NCBI谷歌学术
25.里斯·RM，赫尔泽·KT，艾伦·KO，郑C，索洛丁·N，阿拉里德·ET。GRHL2增强磷酸化雌激素受体（ER）染色质的结合，并调控ER介导的转录激活和抑制。分子细胞生物学，2022年;42（10）：e0019122。PMID：36036613
查看文章PubMed/NCBI谷歌学术
26.科切·KJ、贾斯珀·JS、德索特尔斯·TK、埃弗雷特·L、沃德尔·S、韦斯特林·T等。谱系决定因子GRHL2与FOXA1合作，建立内分泌耐药性乳腺癌的靶向通路。细胞代表 2019;29（4）：889-903。第10页。PMID：31644911
查看文章PubMed/NCBI谷歌学术
27.威拉诺夫斯基·T，塔克菲尔德·A，切鲁蒂·L，奥康奈尔·S，圣R，帕雷克·V等。一个高度保守的哺乳动物发育转录因子家族，与果蝇颗粒头蝇相关。机甲开发 2002;114(1–2):37–50.PMID：12175488
查看文章PubMed/NCBI谷歌学术
28.雅各布斯法官、阿特金斯·M、戴维·K、伊姆里乔娃·H、罗曼内利·L、克里斯蒂安斯·V等。转录因子颗粒头通过置换核小体，启动上皮增强子以实现时空激活。纳特·热内。2018;50(7):1011–20.PMID：29867222
查看文章PubMed/NCBI谷歌学术
29.明Q、罗斯克Y、舒茨A、瓦伦丁K、Ibraimi I、施密特-奥特KM等。Grainyhead/CP2转录因子家族基因调控的结构基础。核酸研究 2018;46(4):2082–95.PMID：29309642
查看文章PubMed/NCBI谷歌学术
30.文卡特桑 K，麦克马纳斯 HR，梅洛 CC，史密斯 TF，汉森 U。古代复制转录因子家族成员之间的功能保守性，LSF/格雷尼头。核酸研究，2003年;31(15):4304–16.PMID：12888489
查看文章PubMed/NCBI谷歌学术
31.Mohammed H， Taylor C， Brown GD， Papachristou EK， Carroll JS， D'Santos CS. 内源性蛋白快速免疫沉淀质谱（RIME）用于染色质复合物分析。纳特·普罗托克。2016;11(2):316–26.PMID：26797456
查看文章PubMed/NCBI谷歌学术
32.麦克福恩一世、威尔逊·H、塞尔斯·拉、莱顿一世、塞雷布里斯基一世、布莱克利·RC等。Grainyhead-like-2通过与表观遗传修饰因子的相互作用赋予NK敏感性。Mol免疫。2019;105:137–49.PMID：30508726
查看文章PubMed/NCBI谷歌学术
33.拉马穆尔蒂·L、巴伯·V、塔克菲尔德·A、克劳斯顿·D、托普汉姆·D、坎宁安·JM等。针对CP2基因的靶向破坏，CP2基因是NTF家族的转录因子成员。《生物化学杂志》2001年;276(11):7836–42.PMID：10995745
查看文章PubMed/NCBI谷歌学术
34.Thomas PD、Ebert D、Muruganujan A、Mushayahama T、Albou L-P、Mi H. PANTHER：让基因组尺度的系统发生学对所有人开放。《蛋白质科学》2022年;31(1):8–22.PMID：34717010
查看文章PubMed/NCBI谷歌学术
35.穆罕默德·H，拉塞尔·IA，斯塔克·R，鲁埃达·奥姆，希基·TE，塔鲁利·乔治亚州等。孕酮受体调节乳腺癌中的ERα作用。自然。2015;523(7560):313–7.PMID：26153859
查看文章PubMed/NCBI谷歌学术
36.汉夫·D、法辛·P、加斯·P、马蒂亚斯·W·贝克曼、哈克·CC、海因德尔·F等。CCND1扩增对激素受体阳性、HER2阴性乳腺癌患者的预后影响——临床和病理标志物的相关性。乳腺癌治疗。2025;210(1):125–34.PMID：39586971
查看文章PubMed/NCBI谷歌学术
37.雷内里·S、阿加蒂·S、米亚诺·V、萨尼·M、贝尔奇亚拉·P、里奇·L等。Tab2的一种新功能结构域，参与乳腺癌细胞中雌激素受体α的相互作用。PLoS One。2016;11（12）：e0168639。PMID：27992601
查看文章PubMed/NCBI谷歌学术
38.扎乌林·R、费拉里·R、纳赫特·AS、卡博内尔·J、勒·迪利·F、丰特-马图·J等。一组可及增强剂使乳腺癌细胞能够对生理孕素浓度做出初步反应。核酸研究 2021;49(22):12716–31.PMID：34850111
查看文章PubMed/NCBI谷歌学术
39.罗宾逊·JT，索瓦尔兹多蒂尔·H，温克勒·W，古特曼·M，兰德·ES，盖茨·G等。整合基因组学查看器。纳特生物技术。2011;29(1):24–6.PMID：21221095
查看文章PubMed/NCBI谷歌学术
40.Wang Q、Li M、Wu T、Zhan L、Li L、Chen M 等。通过 ChIPseek 探索表观基因组数据集。柯尔·普罗托克。2022;2（10）：e585。PMID：36286622
查看文章PubMed/NCBI谷歌学术
41.余G，王L-G，何Q-Y。ChIPseeker：一款用于 ChIP 峰值标注、比较和可视化的 R/Bioconductor 软件包。生物信息学。2015;31(14):2382–3.PMID：25765347
查看文章PubMed/NCBI谷歌学术
42.Ramírez-Cuéllar J， Ferrari R， Sanz RT， Valverde-Santiago M， García-García J， Nacht AS 等。LATS1 控制 3D 培养乳腺癌细胞的 CTCF 染色质占有及激素反应。EMBO J. 2024; 43(9):1770–98. PMID：38565950
查看文章PubMed/NCBI谷歌学术
43.Yang L， Kumegawa K， Saeki S， Nakadai T， Maruyama R. 通过染色质可及性剖析，识别乳腺癌细胞系中谱系特异性表观遗传调控因子FOXA1和GRHL2。癌症基因 Ther. 2024; 31(5):736–45. PMID：38429368
查看文章PubMed/NCBI谷歌学术
44.Heinz S、Benner C、Spann N、Bertolino E、Lin YC、Laslo P 等。谱系决定转录因子的简单组合为巨噬细胞和B细胞身份所需的顺调调元素。Mol细胞。 2010; 38(4):576–89. PMID：20513432
查看文章PubMed/NCBI谷歌学术
45.de Bruijn I、Kundra R、Mastrogiacomo B、Tran TN、Sikina L、Mazor T 等。AACR Project GENIE 生物制药协作项目中纵向基因组和临床数据的分析与可视化，载于 cBioPortal。癌症研究 2023; 83(23):3861–7. PMID：37668528
查看文章PubMed/NCBI谷歌学术
46.柯蒂斯·C、沙阿警长、秦S-F、图拉什维利·G、鲁埃达·OM、邓宁·MJ等。2000个乳腺肿瘤的基因组和转录组结构揭示了新的亚群。自然。2012;486(7403):346–52.PMID：22522925
查看文章PubMed/NCBI谷歌学术
47.道森 S-J，鲁埃达 OM，阿帕里西奥 S，卡尔达斯 C.一种新的基因组驱动综合乳腺癌综合分类及其影响。EMBO J. 2013;32(5):617–28.PMID：23395906
查看文章PubMed/NCBI谷歌学术
48.佩雷拉·B、秦S-F、鲁埃达·OM、沃兰·H-KM、普罗文扎诺·E、巴德韦尔·HA等。2433例乳腺癌的体细胞突变谱进一步完善了其基因组和转录组图谱。国家公社。2016;7:11479.PMID：27161491
查看文章PubMed/NCBI谷歌学术
49.徐S、胡娥、蔡毅、谢子、罗晓、展L等。使用 clusterProfiler 来刻画多组学数据。纳特·普罗托克。2024;19(11):3292–320.PMID：39019974
查看文章PubMed/NCBI谷歌学术
50.姚·L，伯曼·BP，法纳姆PJ。揭开增强子的秘密使命：将远端调控元件与目标基因连接。2015年生物化学分子生物学评论;50(6):550–73.PMID：26446758
查看文章PubMed/NCBI谷歌学术
51.桑亚尔·A，拉乔伊·BR，贾因·G，德克尔·J。基因启动子的远程相互作用景观。自然。2012;489(7414):109–13.PMID：22955621
查看文章PubMed/NCBI谷歌学术
52.李G、阮X、奥尔巴赫RK、桑杜KS、郑M、王P等。广泛的启动子中心染色质相互作用为转录调控提供了拓扑基础。Cell。2012;148(1–2):84–98.PMID：22265404
查看文章PubMed/NCBI谷歌学术
53.米夫苏德·B、塔瓦雷斯-卡德特·F、杨·AN、舒格·R、舍恩费尔德·S、费雷拉·L等。利用高分辨率捕捉Hi-C绘制人体细胞中远程启动子接触图。纳特·热内。2015;47(6):598–606.PMID：25938943
查看文章PubMed/NCBI谷歌学术
54.Tettey TT、Rinaldi L、Hager GL。激素依赖性癌症中的远程基因调控。纳特·雷夫·癌症。2023;23(10):657–72.PMID：37537310
查看文章PubMed/NCBI谷歌学术
55.金F、李Y、迪克森JR、塞尔瓦拉杰S、叶Z、李AY等。人体细胞三维染色质相互作用组的高分辨率图谱。自然。2013;503(7475):290–4.PMID：24141950
查看文章PubMed/NCBI谷歌学术
56.Handoko L， Xu H， Li G， Ngan CY， Chew E， Schnapp M 等。CTCF 介导的功能性染色质相互作用组在多能细胞中。纳特·热内。2011;43(7):630–8.PMID：21685913
查看文章PubMed/NCBI谷歌学术
57.勒迪利 F、鲍 D、波尔 A、维森特 GP、塞拉 F、索罗内拉斯 D 等。染色质拓扑结构域的不同结构转变与激素诱导的基因调控协调相关。基因开发 2014;28(19):2151–62.PMID：25274727
查看文章PubMed/NCBI谷歌学术
58.Holding AN、Giorgi FM、Donnelly A、Cullen AE、Nagarajan S、Selth LA 等。VULCAN 将 ChIP-seq 与患者来源的共表达网络整合，以识别 GRHL2 作为乳腺癌增强子 ERa 的关键共调控因子。基因组生物学，2019年;20(1):91.PMID：31084623
查看文章PubMed/NCBI谷歌学术
59.Paltoglou S、Das R、Townley SL、Hickey TE、Tarulli GA、Coutinho I 等。新型雄激素受体协调剂 GRHL2 在前列腺癌中同时发挥致癌和抗转移功能。癌症研究 2017;77(13):3417–30.PMID：28473532
查看文章PubMed/NCBI谷歌学术
60.Grift YB van de、Aarts MT、Wiese KE、Heijmans N、Hooijkaas IB、Pritchard CE 等。GRHL和PGR通过3D循环控制乳房腺中WNT4表达，这些增强子是保守且物种特异性增强子的[互联网]。2025年[引用于2025年6月6日];2025.04.11.648333。可从以下网站获取：https://www.biorxiv.org/content/10.1101/2025.04.11.648333v1
61.Bernardo GM、Bebek G、Ginther CL、Sizemore ST、Lozada KL、Miedler JD 等。FOXA1抑制基底乳腺癌细胞的分子表型。癌基因。2013;32(5):554–63.PMID：22391567
查看文章PubMed/NCBI谷歌学术
62.Bernardo GM、Lozada KL、Miedler JD、Harburg G、Hewitt SC、Mosley JD 等。FOXA1是ERalpha表达和乳腺导管形态发生的重要决定因子。发展。2010;137(12):2045–54.PMID：20501593
查看文章PubMed/NCBI谷歌学术
63.刘毅、赵毅、斯凯里·B、王X、科林-卡辛C、拉迪斯基·DC等。Foxa1对乳管形成至关重要。创世纪。2016;54(5):277–85.PMID：26919034
查看文章PubMed/NCBI谷歌学术
64.塞巴洛斯-查韦斯中场，苏布蒂尔-罗德里格斯中场，贾诺普卢 EG，索罗内拉斯后卫，巴斯克斯-查韦斯 E，维森特 GP 等。染色质重塑剂CHD8是激活孕酮受体依赖增强子所必需的。《公共图书馆》Genet。2015;11（4）：e1005174。PMID：25894978
查看文章PubMed/NCBI谷歌学术
65.Siersbæk R、Scabia V、Nagarajan S、Chernukhin I、Papachristou EK、Broome R 等。IL6/STAT3信号诱导雌激素受体α增强子驱动乳腺癌转移。癌症细胞。2020;38（3）：412-423.e9。PMID：32679107
查看文章PubMed/NCBI谷歌学术
66.Gooch JL， Christy B， Yee D. STAT6介导人类乳腺癌细胞中白介介素-4增生抑制。肿瘤。2002;4(4):324–31.PMID：12082548
查看文章PubMed/NCBI谷歌学术
67.Hughes CS，Foehr S，Garfield DA，Furlong EE，Steinmetz LM，Krijgsveld J。利用顺磁珠技术进行超灵敏蛋白质组分析。分子系统生物学，2014年;10(10):757.PMID：25358341
查看文章PubMed/NCBI谷歌学术
68.Aarts MT，Wagner M，van der Wal T，van Boxtel AL，van Amerongen R.一个用于研究孕酮受体信号传导的分子工具箱。《乳腺生物肿瘤杂志》。2023;28(1):24.PMID：38019315
查看文章PubMed/NCBI谷歌学术
69.van de Grift YB、Aarts MT、Wiese KE、Heijmans N、Hooijkaas IB、Pritchard CE 等人。GRHL和PGR通过3D循环控制保守且物种特异性增强子在乳腺中的WNT4表达。bioRxiv。2025.
查看文章谷歌学术
70.Ewels P、Magnusson M、Lundin S、Käller M. 多质量检测：在一份报告中总结多个工具和样本的分析结果。生物信息学。2016;32(19):3047–8.PMID：27312411
查看文章PubMed/NCBI谷歌学术
71.Trimmomatic：用于Illumina序列数据的灵活剪裁器 |生物信息学 |牛津学术 [互联网]。[引自2024年11月26日];可从以下网站获取：https://academic.oup.com/bioinformatics/article/30/15/2114/2390096
72.Kim D、Paggi JM、Park C、Bennett C、Salzberg SL。基于图表的基因组比对与基因分型，利用HISAT2和HISAT基因型进行。纳特生物技术。2019;37(8):907–15.PMID：31375807
查看文章PubMed/NCBI谷歌学术
73.Anders S， Pyl PT， Huber W. HTSeq——一个用于处理高通量测序数据的Python框架。生物信息学。2015;31(2):166–9.PMID：25260700
查看文章PubMed/NCBI谷歌学术
74.Love MI， Huber W， Anders S. 利用DESeq2对RNA-seq数据的折叠变化和扩散进行调节估计。基因组生物学，2014年;15(12):550.PMID：25516281
查看文章PubMed/NCBI谷歌学术
75.Chua SL、参见 Too WC、Khoo BY、Few LL。UBC 和 YWHAZ 是使用 MCF7、HCT116 和 HepG2 细胞系进行基因表达准确规范化的合适参考基因。细胞技术。2011;63(6):645–54.PMID：21850463
查看文章PubMed/NCBI谷歌学术
76.赞巴尼尼·G，诺尔丁·A，约纳森·M，帕杰拉·P，坎图·C。一种针对转录辅因子优化的新型CUT&RUN低容积尿素（LoV-U）协议揭示了Wnt/β-catenin组织特异性基因组靶点。发展。2022;149（23）:d ev201124。PMID：36355069
查看文章PubMed/NCBI谷歌学术
77.de Sena Brandine G， Smith AD. Falco：用于测序数据质量控制的高速快速QC仿真。F1000Res。2019;8:1874.PMID：33552473
查看文章PubMed/NCBI谷歌学术
78.布什内尔B、鲁德J、辛格E。BBMerge——通过重叠准确的双枪判读并线。PLoS One。2017;12（10）：e0185056。PMID：29073143
查看文章PubMed/NCBI谷歌学术
79.Langmead B，Salzberg SL。与蝴蝶结2的快速间隙读比对。自然方法。2012;9(4):357–9.PMID：22388286
查看文章PubMed/NCBI谷歌学术
80.李H、汉德萨克B、怀索克A、芬奈尔T、阮J、霍默N等。序列比对/图谱格式和SAM工具。生物信息学。2009;25(16):2078–9.PMID：19505943
查看文章PubMed/NCBI谷歌学术
81.阿肯色州昆兰，霍尔内科。BEDTools：一套灵活的工具组合，用于比较基因组特征。生物信息学。2010;26(6):841–2.PMID：20110278
查看文章PubMed/NCBI谷歌学术
82.诺尔丁·A，赞巴尼尼·G，帕杰拉·P，坎图·C。CUT&RUN怀疑基因组中存在问题区域。《基因组生物学》2023年;24(1):185.PMID：37563719
查看文章PubMed/NCBI谷歌学术
83.张毅、刘T、迈耶CA、Eeckhoute J、约翰逊DS、伯恩斯坦BE等。基于模型的ChIP-Seq（MACS）分析。基因组生物学，2008年;9（9）：R137。PMID：18798982
查看文章PubMed/NCBI谷歌学术
84.Bolger AM， Lohse M， Usadel B. Trimmomatic：用于Illumina序列数据的柔性剪裁器。生物信息学。2014;30(15):2114–20.PMID：24695404
查看文章PubMed/NCBI谷歌学术
85.Amemiya HM，Kundaje A，Boyle AP。《ENCODE黑名单：基因组问题区域的识别》。科学报告 2019;9(1):9354.PMID：31249361
查看文章PubMed/NCBI谷歌学术
86.Ramírez F、Dündar F、Diehl S、Grüning BA、Manke T. deepTools：一个用于探索深度测序数据的灵活平台。核酸研究，2014年;42（网页服务器问题）：W187-91。PMID：24799436
查看文章PubMed/NCBI谷歌学术
87.Zou Z， Ohta T， Oki S. ChIP-Atlas 3.0：一套数据挖掘套件，用于探索染色体结构及大规模调节组数据。核酸研究 2024;52（W1）：W45–53。PMID：38749504
查看文章PubMed/NCBI谷歌学术
88.Carenzo A、Pistore F、Serafini MS、Lenoci D、Licata AG、De Cecco L. hacksig：一个统一且整洁的R框架，用于轻松计算基因表达签名评分。生物信息学。2022;38(10):2940–2.PMID：35561166
查看文章PubMed/NCBI谷歌学术
89.Therneau M， Grambsch PM。《生存数据建模：扩展Cox模型》。
90.瑟诺·T。R语言中的生存分析包[互联网]。2026;可从以下网站获取：https://CRAN.R-project.org/package=survival
91.Kassambara A、Kosinski M、Biecek P. survminer：使用ggplot2绘制生存曲线 [互联网]。2025;可从以下网站获取：https://CRAN.R-project.org/package=survminer
引进/卖出
2026-03-18
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
临床1期
2026-03-17
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
100 项与 盐酸利匹韦林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2011-05-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 怀孕 | 临床3期 | 美国 | 2009-04-09 | |
| 肝炎 | 临床1期 | 美国 | 2011-11-01 | |
| 丙型肝炎 | 临床1期 | - | 2010-11-01 | |
| 避孕 | 临床1期 | - | 2008-07-01 | |
| 避孕行为 | 临床1期 | - | 2008-07-01 | |
| 获得性免疫缺陷综合征 | 临床1期 | - | 2008-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 306 | 衊醖選積窪鹹選顧餘構(願艱壓餘觸淵窪壓顧廠) = 淵顧選蓋鬱壓簾壓積觸 範簾憲齋襯鹽簾繭鹹糧 (願憲鏇齋繭憲網構顧遞 ) 更多 | 积极 | 2026-02-26 | |||
Standard care | 衊醖選積窪鹹選顧餘構(願艱壓餘觸淵窪壓顧廠) = 積壓簾衊蓋鬱壓顧獵築 範簾憲齋襯鹽簾繭鹹糧 (願憲鏇齋繭憲網構顧遞 ) 更多 | ||||||
临床3期 | 396 | Cabotegravir+rilpivirine (CAB+RPV) LA Q2M with a 1-month optional once-daily OLI of CABRPV) LA Q2M with a 1-month optional once-daily OLI of CAB+RPV | 憲簾鑰簾糧夢廠鏇觸壓(願壓築鑰膚齋遞觸廠範) = 廠鑰衊願齋製醖餘膚遞 糧顧齋鏇艱簾餘壓鑰觸 (鏇遞醖製糧糧繭鏇醖遞 ) 更多 | 积极 | 2025-12-01 | ||
憲簾鑰簾糧夢廠鏇觸壓(願壓築鑰膚齋遞觸廠範) = 獵齋遞糧膚衊鑰壓範齋 糧顧齋鏇艱簾餘壓鑰觸 (鏇遞醖製糧糧繭鏇醖遞 ) 更多 | |||||||
临床3期 | 145 | 膚蓋艱繭壓繭鑰鑰製鹽(鬱衊選製餘範顧襯膚蓋) = 築觸願鹽構鑰糧觸獵夢 壓醖夢壓淵襯齋醖壓膚 (網觸鬱築顧廠鏇衊淵積 ) 更多 | 积极 | 2025-07-14 | |||
临床3期 | 456 | (Step 2 Arm A: LA ART) | 鬱襯憲鑰壓鹹鑰艱構醖 = 鬱鬱廠餘願襯衊膚衊鏇 製夢襯衊顧網顧鹹繭網 (觸簾獵襯簾築選鑰壓簾, 構鏇繭觸膚窪選艱簾衊 ~ 蓋膚製窪觸築壓窪窪夢) 更多 | - | 2025-04-24 | ||
Standard of Care (SOC) Oral ART (Step 2 Arm B: SOC) | 鬱襯憲鑰壓鹹鑰艱構醖 = 壓鏇夢獵觸觸窪觸鬱膚 製夢襯衊顧網顧鹹繭網 (觸簾獵襯簾築選鑰壓簾, 膚繭夢醖觸鹽壓糧窪窪 ~ 選憲鑰選淵鬱糧餘廠網) 更多 | ||||||
临床1/2期 | 139 | 鑰衊餘醖艱廠廠餘餘淵(範廠膚夢積鑰壓壓糧遞) = 10.8% [95% CI 6.2-17.2] of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24 選鏇憲獵鏇醖製壓衊鹹 (築餘衊膚糧醖構網齋觸 ) 更多 | 积极 | 2025-03-01 | |||
临床2期 | 54 | (Cohort 1 Adolescents: Rilpivirine 25 mg) | 積顧蓋膚餘廠齋獵製獵(範積齋夢鹹選選餘網夢) = 鹽觸艱窪窪襯壓窪鹹積 獵醖觸蓋選鬱艱積獵鏇 (憲遞鏇顧窪齋積獵齋襯, 38.0) 更多 | - | 2024-06-25 | ||
(Cohort 2 Children (>=25 kg): Rilpivirine 25 mg) | 積顧蓋膚餘廠齋獵製獵(範積齋夢鹹選選餘網夢) = 夢膚願夢餘簾醖襯蓋鹹 獵醖觸蓋選鬱艱積獵鏇 (憲遞鏇顧窪齋積獵齋襯, 52.2) 更多 | ||||||
临床1/2期 | 168 | Combination Antiretroviral Therapy (cART)+Long-Acting Injectable Cabotegravir (CAB LA) (Cohort 1C: CAB) | 憲製選獵齋窪簾夢鏇蓋 = 鬱遞範艱積構淵膚構築 獵壓鬱願蓋鹽襯積簾遞 (窪遞獵鬱夢壓顧構積鬱, 鹽醖醖鹽蓋觸範衊鬱獵 ~ 獵鬱膚憲積衊積憲鏇鑰) 更多 | - | 2024-05-14 | ||
Combination Antiretroviral Therapy (cART)+RPV (Cohort 1R: RPV) | 憲築觸鹽願艱簾膚淵網 = 壓製壓淵繭製鹽醖繭夢 顧築餘襯製鹽網遞蓋範 (構齋獵構壓廠簾願鏇獵, 餘願構糧獵遞構艱鑰簾 ~ 構獵觸鏇鹹製願蓋鑰構) 更多 | ||||||
临床2期 | 26 | (Rilpivirine 12.5 Milligrams (mg) (<20 kg)) | 觸獵襯餘範壓蓋繭壓鏇(築簾蓋憲積獵夢壓餘廠) = 簾鏇鏇廠糧鏇壓範鑰憲 醖顧網蓋膚網繭糧糧夢 (齋膚鏇醖醖壓遞艱艱憲, NA) 更多 | - | 2024-05-02 | ||
(Rilpivirine 15 mg (<20 kg)) | 糧鹽淵顧鹽構鑰獵襯範(窪積鹽廠餘膚選遞積範) = 鏇網糧網構夢夢襯範齋 艱觸顧艱鹹廠襯鑰餘願 (鬱觸蓋鹽廠繭簾衊構遞, NA) 更多 | ||||||
临床1期 | 15 | (IM CAB 600 mg) | 夢憲膚鑰遞醖鹽願鑰鏇(積積鹹窪獵積簾膚憲糧) = 蓋蓋淵鑰簾淵膚窪鏇糧 糧積壓顧艱繭簾鬱壓遞 (廠簾構製鬱鏇鑰觸鹽製, 66) 更多 | - | 2024-04-22 | ||
(IM RPV 900mg) | 獵蓋鏇餘醖廠醖糧鹽顧(夢餘鬱廠醖醖製鏇遞膚) = 簾窪鹽鹽範鬱醖網積範 顧製遞獵餘廠鑰膚夢廠 (襯鏇鹹醖膚鹽選艱築觸, 37.7) 更多 | ||||||
临床2期 | - | EDURANT+BR (HIV RNA ≤100,000) | 廠淵蓋窪繭衊艱鹽獵糧(蓋襯鏇廠觸淵獵選繭製) = 獵衊鬱憲鏇顧膚網鏇鑰 鏇獵築壓遞構簾齋餘遞 (餘餘壓網範繭簾窪遞壓 ) 更多 | 优效 | 2024-03-15 | ||
EDURANT+BR (HIV RNA >100,000) | 廠淵蓋窪繭衊艱鹽獵糧(蓋襯鏇廠觸淵獵選繭製) = 膚鏇積製襯膚糧範衊窪 鏇獵築壓遞構簾齋餘遞 (餘餘壓網範繭簾窪遞壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用